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ABSTRACT 
Gupta, Manav. M.S., Purdue University, August 2013. Differentiation and Characterization of 
Cell types Associated with Retinal Degenerative Diseases Using Human Induced Pluripotent 
Stem Cells. Major Professor: Jason S. Meyer 
 
 
 
Human induced pluripotent stem (iPS) cells have the unique ability to differentiate into 200 or so 
somatic cell types that make up the adult human being. The use of human iPS cells to study 
development and disease is a highly exciting and interdependent field that holds great promise in 
understanding and elucidating mechanisms behind cellular differentiation with future applications 
in drug screening and cell replacement studies for complex and currently incurable cellular 
degenerative disorders. The recent advent of iPS cell technology allows for the generation of 
patient-specific cell lines that enable us to model the progression of a disease phenotype in a 
human in vitro model. Differentiation of iPS cells toward the affected cell type provides an 
unlimited source of diseased cells for examination, and to further study the developmental 
progression of the disease in vitro, also called the “disease-in-a-dish” model.  
 
In this study, efforts were undertaken to recapitulate the differentiation of distinct retinal cell 
affected in two highly prevalent retinal diseases, Usher syndrome and glaucoma. Using a line of 
Type III Usher Syndrome patient derived iPS cells efforts were undertaken to develop such an 
approach as an effective in vitro model for studies of Usher Syndrome, the most commonly 
inherited disorder affecting both vision and hearing. Using existing lines of iPS cells, studies 
 
 
 
	  
xiii 
were also aimed at differentiation and characterization of the more complex retinal cell types, 
retinal ganglion cells (RGCs) and astrocytes, the cell types affected in glaucoma, a severe 
neurodegenerative disease of the retina leading to eventual irreversible blindness.  
 
Using a previously described protocol, the iPS cells were directed to differentiate toward a retinal 
fate through a step-wise process that proceeds through all of the major stages of neuroretinal 
development. The differentiation process was monitored for a period of 70 days for the 
differentiation of retinal cell types and 150 days for astrocyte development. The different stages 
of differentiation and the individually derived somatic cell types were characterized by the 
expression of developmentally associated transcription factors specific to each cell type. Further 
approaches were undertaken to characterize the morphological differences between RGCs and 
other neuroretinal cell types derived in the process.  
 
The results of this study successfully demonstrated that Usher syndrome patient derived iPS cells 
differentiated to the affected photoreceptors of Usher syndrome along with other mature retinal 
cell types, chronologically analogous to the development of the cell types in a mature human 
retina. This study also established a robust method for the in vitro derivation of RGCs and 
astrocytes from human iPS cells and provided novel methodologies and evidence to characterize 
these individual somatic cell types.  
 
Overall, this study provides a unique insight into the application of human pluripotent stem cell 
biology by establishing a novel platform for future studies of in vitro disease modeling of the 
retinal degenerative diseases: Usher syndrome and glaucoma. In downstream applications of this 
study, the disease relevant cell types derived from human iPS cells can be used as tools to further 
study disease progression, drug screening and cell replacement strategies.   
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CHAPTER 1 – INTRODUCTION 
 
 
 
1.1 Nervous System and Development 
The specialization of the more than 200 cell types that constitute the adult human body starts 
during gastrulation, an early embryonic developmental process when the embryo differentiates 
into the 3 germ layers – ectoderm, mesoderm, and endoderm – 14 to 16 days post-fertilization 
(http://stemcells.nih.gov/info/scireport/pages/appendixa.aspx). The nervous system, consisting of 
the brain, retina, spinal cord, and the collection of nerves and glia that together control all sensory 
and motor responses of the human body, is derived from the ectoderm within the first 3 weeks 
post-fertilization. The development of the nervous system starts when inductive signals from the 
mesoderm that induces the overlying layer of ectoderm to thicken and flatten out to form the first 
stage in nervous system development, the neural plate [1]. The neural plate can be considered to 
be a row of multipotent neural stem cells that eventually gives rise to all the parts of the central 
nervous system [2]. The ends of the neural plate gradually folds on itself creating the neural 
groove. This neural groove deepens further as the folds eventually close together to form the 
neural tube, the precursor structure now primed for the regional specification of the nervous 
system [1]. The anterior parts of the developing neural tube give rise to primary brain vesicles, 
the prosencephelon, mesencephelon, and the rhombencephelon. The remaining posterior regions 
give rise to the spinal cord. Molecular signals are responsible for further patterning the neural 
tube along the anterior-posterior and dorsal-ventral axes. The primary brain vesicles are further 
divided into secondary brain vesicles that give rise to different parts of the brain and the inferior 
regions continue to specialize into different regions of the spinal cord. Around 30-35 days of 
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development in humans, the prosencephelon divides into telencephalon and the diencephalon. 
The telencephalon forms the anterior most forebrain regions of the nervous system, the cerebral 
cortex, white matter, and the basal ganglia. The diencephalon, which is directly inferior to the 
developing cerebral cortex, differentiates into distinct regions forming the retina, thalamus, and 
the hypothalamus. The mesencephelon divides into the midbrain forming the tectum, the region 
critical in processing visual and auditory responses, and tegmentum, the region that controls 
motor and other reflexive pathways. The rhombencephelon is further divided into metencephelon 
and myelencephelon. The metencephelon forms the motor center of the brain, the cerebellum, and 
the pons. The myelencephelon forms the medulla oblongata, the respiratory control center of the 
nervous system and control center for other involuntary functions like heart beat rate, blood 
pressure, and other autonomic functions. The spinal cord formation is continuous with the 
medulla oblongata. All regions of the nervous system are essentially composed of several types of 
neurons that crosslink and influence each other via synaptic contact to establish an extremely 
intricate system of neural circuitry that along with glial cells govern the functioning of the entire 
nervous system. 
 
1.2 Development of the Eye and Retina 
The retina develops as a bipartite primordium from a single central field of the developing 
anterior neural tube [3] (Figure 1). During the first few weeks of human nervous system 
development, the diencephalon gives rise to a paired set of optic grooves that eventually 
evaginates to form the optic vesicles from a central eye field. The optic vesicles undergo further 
specification and coordination with the head ectoderm to differentiate into bi-layered optic cups 
where the inner layer eventually develops into the neural retina and the outer layer, the supportive 
RPE [4]. The third part of retinal development involves the specification of the optic stalk that 
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matures to form the optic nerve [5]. The part of the head ectoderm in close association with the 
developing optic cup is eventually induced to form the lens [6].  
 
Several defining studies in identifying the ontogeny of the retina and its cell types has provided a 
range of molecular markers to identify individual neuroretinal cell populations and their 
functionalities with precision, making retina a highly accessible and amicable model for the study 
of  nervous system development [7].  
 
The differentiation of specific retinal cell types from the optic cup-stage progenitors is based on 
the activity of lineage restricted progenitors and whose fate can be divided chronologically into 
early and late retinogenesis [8, 9]. The earliest cell types derived in the retina are the retinal 
ganglion cells (RGCs), cone photoreceptors, horizontal cells, and most amacrine cells. Rod 
photoreceptors, bipolar interneurons and Müller	   glia are derived in the latter half of retinal 
development [10, 11]. The early stage of eye field specification has been extensively 
characterized for the expression of stage specific transcription factors and proteins. Early optic-
vesicle structures are characterized by the expression of the eye field transcription factors 
(EFTFs): PAX6, RAX, SIX3, SIX6, LHX2, and TBX3 distinguishing them from other lineages of 
neural commitment [12, 13]. Cell populations co-expressing PAX6 and RAX have been identified 
as definitive retinal progenitor cells in early eye and later retinal specifications [14]. Genetic 
studies corroborate the importance of EFTFs in human eye development by showing how 
mutations in PAX6, SIX3, SIX6 can result in malformations affecting the eyes [6]. Early and late 
stage retinal histogenesis has been similarly studied for the expression of developmentally 
associated factors that play a pivotal role in the understanding of the highly conserved series of 
events that forms the retina and its cell types. More specifically, the role of multiple basic helix-
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loop-helix (bHLH) type transcription factors in combination with other homeobox and forkhead 
genes is crucial for the subsequent lamination of the retinal structure [15] (Figure 2). 
 
The differentiation of retinal neurons begins around 31-35 days of human embryonic 
development [16]. The competence of retinal progenitors to specify a distinct neuroretinal cell 
type is based on the availability of both intrinsic and extrinsic cues. Dividing and proliferating 
multipotent retinal progenitor cells are identified by the expression of the homeobox transcription 
factor, CHX10 [17]. RGCs are determined by the expression of ATH5, a bHLH transcription 
factor transiently expressed in the retinal progenitors cells, essential for the specification of RGCs 
[18-20]. A set of 3 POU domain transcription factors, BRN3A, BRN3B, BRN3C, is expressed in a 
restricted fashion in the RGCs in the retina, as a downstream target for ATH5 [21]. The origin of 
bipolar interneurons is regulated by the bHLH factors MASH1 and MATH3 in coordination with 
the homeobox gene CHX10 [22]. Other interneurons including the amacrine cells and horizontal 
cells are closely associated in development with several overlapping regulatory factors. The 
neural bHLH transcription factors MATH3 and NEUROD are required for the retinal progenitors 
to differentiate to amacrine cells [22] whereas the forkhead factors, FOXN4 and PTF1A are 
critical for both amacrine and horizontal cells. Misexpression of these factors leads to greatly 
reduced amacrine cell numbers and a complete loss of horizontal cells [23, 24]. The expression of 
PROX1 is essential for horizontal cell genesis [25]. The photoreceptors are divided into the early 
derived cone and the latter derived rod photoreceptors. The homeobox genes of OTX2 and CRX 
establish the cues for photoreceptors specification [26, 27]. NRL, a basic leucine zipper 
transcription factor is selectively expressed in the rod photoreceptors through the regulation of 
NR2E3 (TLL), activating rod-specific genes [28, 29].  
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1.3 The Retina and its Cell Types 
The retina forms the photosensitive tissue that lines the posterior surface of our eyes. The 
vertebrate retina harbors a repertoire of major cell types that are developmentally produced 
through the step-wise differentiation of multipotent retinal progenitor cells, derived in early 
vertebrate development from the neuroectoderm [13]. The specification of retinal cell types 
during development proceeds through a series of conserved events, in a highly regulated temporal 
and sequential manner [30]. The mature retina is a tightly layered structure consisting of different 
sets of neural, non-neural and glial cell types (Figure 3). The six sets of neurons that make up the 
neuronal tissue of the retina are part of an intricate retinal circuitry that is interconnected via 
synapses and responsible for the transduction of light to electrical signals required for our 
important sense of sight. The rod and cone photoreceptors form the outermost nerve layer of the 
retina and are the first ones to initiate the electrical cascade of visual function. The electric 
potential changes are relayed to inner layers of the retina, from the photoreceptors to the RGCs 
via synaptic contact with bipolar interneurons. In addition, the retina also has other types of 
interneurons, the amacrine cells and horizontal cells, which regulate the electrical input onto the 
retinal ganglion cells [31]. The ganglion cells convey the final electrical output to different brain 
nuclei via their axons which together form the optic nerve and leave the back of the eye in a 
region called the optic disc. The other cell types that make up the retina include the retinal 
pigment epithelium (RPE), a layer of pigmented epithelial cells on the outermost arc of the retina, 
responsible for the turnover of photoreceptor outer segments, and which also acts as the immune 
center of the eye [32]. The glial cell types found in the retina include the Müller cells that form 
the predominant glial cell type in the retina and aids in visual transduction and provides glial 
support to the retinal neurons [33]. The second kind of glial cells found in the retina are the 
astrocytes which are comparatively less in number and found mainly in the nerve fiber layer and 
the optic nerve head (ONH) of the retina in most mammalian species [34]. They form the major 
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glial cell type that support the non-myelinated optic nerve and are also known to secrete 
extracellular matrix molecules below the ONH where the optic nerve emanates out from the 
sclera at the mesh like structure called the laminar cibrosa [35]. The close coordination of all 
neural and non-neural cell types in the retina is essential for maintaining healthy visual function. 
Any abnormalities in its regular activity can lead to the degeneration of one or more of its specific 
cell types, leading to partial to complete loss of sight. 
 
1.4 Retinal Degenerative Diseases 
 
1.4.1 Background Information 
According to World Health Organization (WHO) the total estimated number of visually impaired 
people as of 2012 stands at an astonishing 285 million (http://www.who.int/topics/blindness/en/). 
An overwhelming 165 million people worldwide are known to be afflicted with retinal diseases 
that cannot be prevented by corrective measures and/ or is currently completely incurable.  
 
As described before, the retina is a thin layer of light-sensitive neural tissue at the back of the eye, 
made of rods and cones and other neurons that function together as part of a neural circuitry for 
relaying and processing visual information. Cell death of any of its several neuroretinal cell types 
can lead to retinal degeneration affecting visual output at different levels. Retinal degeneration 
can manifest itself due to genetic and age-related problems, affecting both the young and old from 
different races, ethnicities, and countries [36]. The limited ability for intrinsic regeneration in the 
mammalian retina makes it highly susceptible to irreversible damage or injury [37]. The degree 
and type of visual deterioration can vary from partial to complete loss of sight depending on type 
and stage of disease. Although different retinal neuron populations are affected in several retinal 
diseases, the loss of photoreceptors is often the initial and primary reason for the loss of other cell 
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types [37]. Glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP) 
are among the leading causes of blindness due to cellular degeneration of specific neuroretinal 
cell types in the retina. The onset of retinal degeneration and loss of sight due to these diseases 
however can progress rapidly or perpetuate slowly in middle to late adulthood [38]. The causes 
for visual impairment can encompass abnormalities in different parts of the eye including the 
lens, choroid, ocular muscles, and vitreous body, however the therapeutic interventions currently 
available for cell based degeneration diseases in the retina are still quite limited compared to 
diagnostic advancements of the field [39]. Most of the diseases of the retina caused by the death 
of one or more of its neurons are currently incurable. Efforts to transplant healthy retinal cell 
types to replace their degenerated counterparts are considered to be the most primary approach 
for the prospective treatment of these diseases. 
 
 
1.4.2 Retinal Diseases – Examples 
 
The retina can be subject to several complex neuropathies affecting one or more of its cell types. 
Age-related diseases such as glaucoma are characterized by the progressive loss of RGCs, and 
AMD, by the gradual loss of photoreceptors, interneurons, and essential supporting cells, the 
RPE. Leading inheritable or genetic retinal disorders include RP, Stargardt’s disease, Best 
disease, Leber’s Congenital Amaurosis. These diseases progress with the early loss of 
photoreceptors with the subsequent loss of RGCs [40]. 
 
Glaucoma, the second largest cause of blindness in the world according to the website of WHO 
(http://www.who.int/bulletin/volumes/82/11/feature1104/en/) is an optic neuropathy, affecting 
visual function and ONH morphology due to the loss of RGC cell bodies and axons in the inner 
retina, nerve fiber layer and ONH respectively [41, 42]. In addition, the lamina cibrosa, openings 
where ganglion cell axons exit the eye, deteriorates progressively. Glaucoma is closely associated 
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with the rise in fluid pressure of the aqueous humor. The increase in intraocular pressure is 
theorized to cause RGC cell death by blocking anterograde and retrograde axonal transport at the 
laminar cibrosa [43, 44]. Glaucoma is divided into 2 main categories: “open angle” and “closed-
angle” type glaucomas [45]. Open-angle glaucoma, the milder of the two sub-types is 
characterized by the slow progression of visual loss starting from the periphery and is diagnosed 
by an increased ratio of the optic cup area to disk. Close-angle glaucoma has a more acute onset 
with higher intraocular pressures due to closure of the angle between the iris and the trabecular 
meshwork which obstructs the flow of the aqueous humor. Close-angle glaucoma can be 
diagnosed by physical symptoms including dilated pupils, clouded cornea, and red eye. While 
there is no current cure for this disease, its progression can be slowed down if detected early. 
However, studies aimed at preventing the loss of RGCs and ONH architecture are more 
pragmatic in terms of providing a definitive solution to this devastating disease.  
 
Age-related macular degeneration (AMD) is an age-related retinal degenerative disease caused by 
the loss of photoreceptors located at the macula region of the retina that affects both central and 
color vision. This painless form of retinopathy has distinct types of pathophysiology. The “dry” 
form of AMD results in the loss photoreceptors in the outermost layer of the retina. It is 
characterized by increased amount of yellow colored extracellular deposits called drusen, 
between the RPE and the choroid. The “wet” form is an exudative form of AMD caused by the 
neovascularization in the sub-retinal space with related macular degeneration. AMD is generally 
seen in elderly people; however, a childhood onset of a type of macular degeneration is known to 
exist in Stargardt’s disease. There are no current cures for AMD, but there are highly promising 
ongoing clinical trials using embryonic stem cell derived RPE cells for sub-retinal transplantation 
into human patients afflicted with the disease [46, 47]. 
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Retinitis pigmentosa (RP) is the leading cause of genetically associated diseases involving retinal 
degeneration in juvenile and early adulthood. RP is a generic name given to all retinal dystrophies 
that progress primarily by affecting the rod photoreceptors first, causing night blindness or 
nyctalopia, and leading eventually to the loss of peripheral and central vision. A total of 45 
causative genes and several mutations have been identified with different forms of RP [48, 49]. 
Physical manifestation of RP includes the deposition of bony-spicule shaped pigmented 
aggregates in the RPE, easily identifiable through the fundus examination of a diseased eye, from 
which the disease gets its name. A fundus examination can also reveal other signs of RP 
including thinning of blood vessels and the pale and waxy appearance of the optic nerve [48]. The 
inheritance pattern of RP shows heterogeneity as also seen with the genes involved in the disease. 
Mutations in RP related genes can be passed on as autosomal dominant, X-linked, and autosomal 
recessive.  An example of an autosomal recessive mutation, and most critical the current study is 
the Usher Syndrome. 
 
Usher Syndrome is the most frequent form of syndromic RP where affected patients suffer from 
visual and auditory abnormalities with some balance defects. The visual loss due to RP 
accompanies mild to severe deafness caused by degenerating neurons in the cochlea part of the 
inner ear. Mutations identified in atleast 10 genes are responsible for Usher syndrome [50, 51]. 
The severity of the progression of the symptoms in Usher syndrome divides it into 3 subtypes 
[52]. In type I, the disease is characterized by congenital deafness and vestibular dysfunction 
accompanied by the loss of night vision before the age of 10. In type II, the patient suffers from 
moderate to severe hearing loss at birth with reduced night vision starting in late childhood and 
no balance issues. Type III is characterized by the onset of sensory problems only in the late teens 
with normal to near-normal vestibular functions. As is the case with other retinal degenerative 
diseases, RP and its related disorders are currently incurable, and strategies including cell 
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replacement, gene therapy, and supplements with neurotrophic factors are promising avenues to 
study the pathophysiology of the disease, and perhaps offer new therapeutic avenues for the 
treatment or cure of the disease.  
 
1.5 Human Pluripotent Stem Cells 
 
1.5.1 Embryonic Stem Cells 
Vertebrate embryogenesis is characterized by the differentiation of the totipotent zygote to all 3 
germ layers including the yolk sac, the amnion, and placenta. The differentiation of all somatic 
and germ cells begins in late stages of the blastocyst when a subset of cells in the inner cell mass 
(ICM) of the blastocyst acquires pluripotent properties before gastrulation. This population of 
around 100 cells derived from the blastocyst stage of the embryo is the embryonic stem (ES) 
cells. The 2 basic properties that distinguish ES cells from any other cell type is its ability to 
differentiate into all adult cell types of the body in addition to the unlimited potential of self-
renewal in culture [53].  
 
ES cells were first derived from mice by the explantation and culture of the ICM of pre-
implantation embryos in seminal works by Evans and Kaufman at Cambridge, and Gail Martin at 
University of California San Francisco [54, 55]. Mouse ES cells injected into the blastocyst of 
mouse embryos were competent of full development, producing chimeric mice where ES cells 
contributed to cell types of all three germ layers as well as the germ line. Further molecular 
characterization of mouse ES cells revealed interesting features when compared to its in vivo 
counterparts. The ICM cells were not self-renewing and globally hypopmethylated compared to 
the unlimited proliferation potential and hypermethylated genomes of ES cells cultured in vitro 
[56, 57].  
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It was not until 17 years after the discovery of mouse ES cells, in 1998, that the first human ES 
cell lines were successfully derived by Thomson and colleagues at the University of Wisconsin 
[58]. Human ES cells were derived from blastocysts of human embryos created by in vitro 
fertilization (IVF) techniques for clinical purposes. Human ES cells were characterized by a 
higher nucleus to cytoplasm ratio, normal karyotype, high telomerase activity, and pre-inactivated 
states of X chromosomes [58, 59]. Human ES cells were also extensively characterized for their 
molecular identifiers and properties. They expressed the pluripotency-associated genes, OCT4, 
SOX2, and NANOG, all of which are highly expressed during embryonic development.  The 
ability of human ES cells to differentiate into cell types of all 3 germ layers was demonstrated by 
the formation of teratomas when injected subcutaneously into immunocompromised mice [58, 60, 
61].  
 
The isolation of mouse and human ES cells ushered in a new era in the field of mammalian 
developmental biology. The endless potential of these cells were realized in theory and then in 
practice for studying basic human development and in the etiology and treatment of diseases. 
Phenomenal concepts of disease modeling and personalized medicine emerged. Strategies for 
directed differentiation of ES cells to individual types of all germ layers including neurons, 
cardiomyocytes, hepatocytes, blood cells, airway epithelial cells, were shown and replicated by 
groups all over the world [62-66]. The use of host or patient derived ES cells by nuclear transfer 
to prevent immune rejection in autologous transplantation and promote repair was shown to be 
successful in a proof-of-principle study in ES-derived dopaminergic neurons in parkinsonian 
mice [67]. The different sources of pluripotent stem cells are summarized in (Figure 4). 
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1.5.2 Induced Pluripotent Stem Cells 
In 2006, an alternative to ES cells was discovered when Yamanaka and colleagues at Kyoto 
University published their landmark study in which the simultaneous introduction of 4 
developmentally associated genes, OCT4, SOX2, KLF-4, C-MYC, into adult mouse fibroblasts 
was able to revert these terminally differentiated cells to a more primitive, unspecified, and 
embryonic-like state [68]. The following year, the labs of both Yamanaka and Thomson 
successfully reprogrammed adult human skin cells to produce the first lines of ES-cell like, 
human induced pluripotent stem (iPS) cells [69, 70]. Human iPS cells were shown to be similar to 
ES cells in several defining attributes including morphology, self-renewing capacity, gene 
expression profile, and most importantly, its differentiation potential and ability to contribute to 
cells of all germ layers. Further molecular characterization of iPS cells reveals that for some 
selective clones they are completely indistinguishable from ES cells in terms of histone tail 
modifications, inactivation states of X chromosomes, and DNA methylation profiles [71].  
 
The emergence of iPS cell colonies in culture is defined by their distinct phase bright and almost 
3-dimensional morphology like appearance characterized by well-defined edges. To tell apart 
colonies that are partially or completely reprogrammed, scientists use the aid of molecular and 
epigenetic identification tools. Completely reprogrammed human iPS cells express endogenously 
activated proteins such as SSEA-4, and surface antigens TRA-1-60 and TRA-1-81 besides the 
expression of the regular cocktail of genes that were used to dedifferentiate the adult cells in the 
first place, OCT4, SOX2, NANOG, LIN28, KLF-4, C-MYC, along with their promoter de-
methylation [72]. Some of the epigenetic hallmarks of iPS cells include the upregulation of de 
novo DNA methyltransferases DNMT3a and DNMT3b, and the role of DNMT1 knockdown to 
convert the intermediately reprogrammed iPS cells into those that are fully pluripotent [73, 74]. 
Tests involving the formation of “all iPSC mice” are the gold standard for mouse iPS cells where 
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one can study the development of a normal mouse only by the iPS cells injected into tetraploid 
embryos, a process known as tetraploid complementation [75-78]. Due to obvious ethical issues 
related to generating human chimeras, the most stringent way to evaluate the developmental 
potential of human iPS cells is its ability to form teratomas upon subcutaneous injection into 
immunodeficient mice [79, 80].  
 
The reproducible nature of iPS technology is evident by the large number of research papers that 
established mouse and human iPS cell lines after the first reports of its derivation was reported 
[80-83]. Alternate animal sources of iPS derivation have also been successful from rats [84, 85], 
rhesus monkeys [86], porcine [87], canines [88], indicating the evolutionary conservation of the 
transcriptional network governing pluripotency in different species and allowing for different 
animal models to be used for disease modeling. Scientists have also generated iPS cells starting 
with different somatic cell populations including blood cells [89], hepatocytes [90], neural cells 
[91], and keratinocytes [92], establishing the overall general applicability of the technology and 
providing alternate cell sources for reprogramming. 
 
The overlapping clinical applications of iPS cells and ES cells are more profound for the former 
due to more immunocompatible cell derivatives for transplantation. The use of iPS cells finds 
limitless potential in normal and diseased forms of human development. The ability to be able to 
generate iPS cells from cells of patients provides a unique way to study disease progression 
compared to isogenic controls and initiate drug screening strategies on affected cell types that can 
be derived from the patient specific iPS cell lines. The use of disease specific iPS cell lines 
provides for means to recapitulate disease phenotype in vitro. One important criterion that 
currently prevents the iPS cells from being autonomously used in clinical trials and making the 
transition from bench to bedside is its association with potential virus like expression and random 
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integration of some of the genes that were initially used to reprogram the adult cells. Since 2006, 
however, several modifications to the protocol of reprogramming has seen the overhaul of the 
initially used retroviral/lentiviral approaches for the more clinically relevant transgene free 
protocols of introduction of the pluripotency associated factors using systems including Sendai 
virus [93], adenovirus [94], plasmids [95], mRNAs [96], proteins [97], and small molecules [98, 
99]. Further sophisticated molecular methodologies to generate transgene free iPS cells include 
the doxycycline drug-inducible and floxed excisable lentiviruses [100, 101]. 
 
The overall impact of the discovery of ES and iPS cells has been potentially revolutionary. 
Although the use of ES and iPS cell technology has great implications in tackling several 
developmental concepts, a great amount of work is still needed to minimize any artifacts 
generated through irregular culturing techniques, non-uniform genetic backgrounds, partial 
reprogramming, and reprogramming factor combinations for these cells to be regularly realized in 
cell transplantation and curative approaches.  
 
1.6 Induced Pluripotent Stem Cells: Disease Modeling 
 
 
 
1.6.1 Disease Modeling in Theory 
 
The successful generation of human iPS cells opened up new avenues of previously unanticipated 
possibilities to study complex degenerative disease in vitro. The role of iPS cells in modeling of 
degenerative disorders will be critical in the near future to gain further insight into identifying 
mechanisms and biological targets associated with disease cause and progression. The concept of 
disease modeling or “disease-in-a-dish” is a promising approach to screen patient derived cell 
types for any genetic or physiological abnormalities and identify novel therapeutic candidates 
which could help combat cellular stresses and disease symptoms (Figure 5). The process works 
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through the derivation of iPS cells from patient specific primary cells followed by the 
differentiation of these cells which bears the genetic memory of the affected individual to the 
disease relevant cell type. The establishment of a cost effective protocol to derive the diseased 
cell type provides an unlimited source of patient tissue that can be used to recapitulate in vivo 
human development and disease phenotypes. The use of patient cells as starting material holds 
tremendous potential for assessing disease progression when compared to cell lines derived from 
isogenic controls of the non-symptomatic individual. The end product of such studies, the in vitro 
derived affected somatic cell types, can be used for a wide range of medical applications 
including transplantation, drug targeting, molecular profiling, and personalized medicine. In 
theory, iPS cells can be differentiated to virtually any tissue type of the body, representing a new 
source of autologous tissue for cell therapy [102].  
 
1.6.2 Disease Modeling in Practice 
A significant amount of work has already been accomplished in the study of degenerative 
disorders of all 3 germ layers including Parkinson’s, Alzheimer’s, Amyotrophic Lateral Sclerosis 
(ALS) or Lou Gehrig’s disease, Retinitis Pigmentosa, Long QT Syndrome, and Type 1 Diabetes. 
Several labs have successfully been able to derive iPS cells from patient specific samples of these 
diseases and provide criterion for differentiation to the affected cell type followed by the 
assessment of in vitro recapitulation of the expected disease phenotype. In the first demonstration 
of this ability of iPS cells, Park and colleagues at Harvard were successful in deriving iPS cells 
with their associated phenotype from different disease patients, including Huntington with its 
characteristic tri-nucleotide CAG repeats in the HUNTINGTIN gene, Down syndrome with the 
triplication of chromosome 21 (trisomy 21) seen in the karyotype analysis, Type 1 Diabetes, and 
Parkinson’s [80]. Work done by labs in individual disease models have shown that not only can 
they reprogram adult cells to the embryonic-like iPS cells but also under specific culture 
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conditions, coax them to differentiate into the cell type associated with the disease including 
motor neurons in Spinal Muscular Atrophy (SMA) and ALS models, beta cells in a diabetes 
model, hematopoietic cell in Fanconi Anemia, and dopamine neurons in Parkinson’s models [80, 
103-106].   
 
In the retina as well, important contributions have been made by different labs in the field of in 
vitro disease modeling and transplantation. Although a lot of the work has been concentrated 
around the use of human ES cells as starting sources, recent studies have picked up the use of iPS 
technology to mimic in vivo retinogenesis in disease patient samples. Gamm and colleagues at 
University of Wisconsin, Madison have generated iPS cells from patients with gyrate atrophy, an 
inherited disorder causing blindness, and used pharmacological (elevated B6 levels) and genetic 
strategies to correct for the genetic mutation in vitro [107]. The ability to model retinal 
degeneration was shown by Takahashi and colleagues at the RIKEN Center for Developmental 
Biology, when they generated iPS cells from 5 patients harboring RP specific mutations in the 
following genes: RP1, RP9, PRPH2, or RHO. The study was successful in recapitulating the 
disease phenotype by measuring the progressive loss of rhodopsin protein over time and 
identified markers for cellular stresses as a consequence of the genetic mutations. The same group 
followed this study with the derivation of RP patient specific iPS cells using a non-integrating 
Sendai-virus vector system to deliver the pluripotency factors for reprogramming a year later 
[108]. In a more recent study, Gamm and colleagues have been successful in modeling the 
maculopathy of BEST disease, an inherited disorder caused by a mutation in the BESTROPHIN1 
gene in the RPE, comparing the properties of iPS-RPE cells derived from the affected patient and 
the unaffected sibling as control [109]. The work demonstrated within this thesis is the first study 
to look at human iPS cells derived from fibroblasts of a Type III Usher Syndrome patient and 
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follow its progression towards a neuroretinal specification, more importantly, toward the affected 
cell type in this disease, photoreceptors.  
 
The use of iPS cells in disease modeling promises for a highly customized approach to studying 
and potentially the development of treatments for several degenerative diseases. However, despite 
the exponential growth of the field en bloc, there is still a constant need for robust protocols to 
achieve and replicate lineage specific differentiation of clinical grade human iPS cells, 
recapitulate disease phenotype, provide functional integration of in vitro derived cells on 
transplantation, and minimize any possible immunogenic reactions in the process. 
 
1.7 Thesis Objectives 
Building on previous studies in the field and utilizing concepts of human iPS cells and directed 
differentiation, this work aims to provide further insight into the specification of distinct retinal 
cell types affected in two major retinal degenerative diseases, Usher syndrome and glaucoma. As 
described earlier, Usher syndrome is a genetically inherited autosomal recessive disease that is 
characterized by the progressive visual loss of first rod photoreceptors and later cones later in 
addition to auditory and vestibular dysfunction. Using iPS cells derived from a patient with Type 
III Usher Syndrome, experiments were designed to assess the developmental potential of this cell 
line towards the recapitulation of a neural and subsequently a retinal phenotype in an in vitro 
system. One of the foremost aims of this study was to establish the chronological order of retinal 
cell fate specification analogous to an in vivo system with a special emphasis on the feasibility of 
this patient specific cell line to derive the affected cell types associated with RP in Usher 
Syndrome, the photoreceptors. The ability of this human iPS cell line to be able to differentiate 
into photoreceptors and all other retinal cell types served a dual purpose. Firstly, it provides a 
robust model to study retinal degeneration events in Usher Syndrome by utilizing the iPS-derived 
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photoreceptors for further downstream applications like studying disease progression, gene 
correction, and potential drug targeting studies. Secondly, being able to derive all other retinal 
neurons and glial cell types that are not associated with Usher Syndrome, the use of this cell line 
and another iPS cell line that was used in the work helps to devise protocols for the derivation, 
characterization, and enhancement of other retinal cell types such as RGCs and astrocytes, 
associated with retinal degeneration in glaucoma, a severe neurodegenerative disease of the retina 
that affects vision. Despite their roles as functionally important cell types in the retina, the 
derivation of RGCs using iPS cells has been very sparsely studied in the field owing to several 
reasons including its unknown in vitro ontogenesis and difficulty of recapitulating the extensive 
in vivo morphologies associated with the cell type in vitro. In the second half of this study, efforts 
were made to establish a timeline for the differentiation of RGCs using human iPS cells and 
provide extensive methods to characterize these projection neurons further. This work also looked 
at the derivation of retinal astrocytes, an important glial cell population at the ONH. Since 
glaucoma is characterized by the remodeling of the ONH, its pathophysiology involves a direct or 
indirect role of these astrocytes in optic nerve degeneration. An important aspect for patient 
specific in vitro modeling of this disease in the future would require the ability of the human iPS 
cells to provide a good robust and plentiful supply of astrocytes along with RGCs. Based on such 
requirements, efforts were made to establish methods to analyze the derivation and 
characterization of iPS-derived astrocytes and in so doing, provide a robust differentiation 
protocol that could be used to derive the two affected somatic cell types in glaucoma.  
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CHAPTER 2 – MATERIALS AND METHODS 
 
 
 
2.1 Cell Culture 
 
2.1.1 Human iPS Cell Lines 
The hiPS cell lines Usher 006.1.5 (Usher iPSC) or T-lymphocyte derived iPS cells (TIPS-5) were 
utilized for all studies. The cell lines were obtained from the lab of Dr. David Gamm at the 
Waisman Center at the University of Wisconsin, Madison. The Usher iPSC line was derived from 
the genetic reprogramming of skin fibroblasts obtained via a skin biopsy from a patient afflicted 
with Type III Usher Syndrome. The TIPS-5 line was established from T-lymphocytes derived 
from a peripheral blood draw from a healthy individual. The derivation of both iPSC lines from 
different somatic cells was based on methods previously established in the field [68, 69, 110].  
 
2.1.2 Media and Media Recipes 
2.1.2.1 Human iPS Cell Medium 
a) mTeSRTM1 Basal Medium (STEMCELLTM Technologies, Catalog #05850) 
b) mTeSRTM1 5X Supplement (STEMCELLTM Technologies, Catalog #05850) 
The final mTeSRTM1 medium was prepared under sterile conditions inside the laminar flow hood. 
The mTeSRTM2IKFFB;C;DJM7IJ>7M;:EL;HD?=>J7J_7D:J>;JEJ7BE<C&J>7M;:2
supplement was aseptically added to 400mL of mTeSRTM1basal medium and mixing well, 
making a total volume of 500mL mTeSRTM1 medium. Complete mTeSRTM1 medium stored at 
_	for up to 2 weeks. 
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2.1.2.2 Neural Induction Medium (NIM) 
For a final volume of 500 mL: 
a) DMEM/F12 (+HEPES) (GIBCOTM, Ref. #11330-032) …………………..................... 489.5mL 
b) N2 Supplement (GIBCOTM, Ref. #17502-048) ……………………………………………. 5mL 
c) MEM-NEAA (GIBCOTM, Ref. #1114-050) ……………………………………………….. 5mL 
d) Heparin …………………………………………………………………………….…….. 0.5mL 
The final volume of NIM was prepared under sterile conditions inside the laminar flow hood. The 
N2 supplement was thawed in a 37_ M7J;H87J> 8;<EH; J>; <EHCKB7J?ED E< J>; C;:?KC .>;
components were added to a 500mL, 0.2µm bottle top filter (Thermo Scientific, Catalog 
#0974107) attached atop a 500mL tissue culture bottle, and the medium was filter-sterilized 
before final usage. NIM was stored 7J_ for up to 2 weeks. 
 
2.1.2.3 Retinal Differentiation Medium (RDM) 
For a final volume of 500 mL: 
a) DMEM/F12 (+HEPES) (GIBCOTM, Ref. #11330-032) …………………........................ 240mL 
b) DMEM (1X) (GIBCOTM, Ref. #12430-054) …………………………………….……… 240mL 
c) B27 Supplement (GIBCOTM, Ref. #17502-048) …………………………………............. 10mL 
d) MEM-NEAA (GIBCOTM, Ref. #1114-050) …………………………………….….…....… 5mL 
e) Penicillin/ Streptomycin/ Ampicillin (PSA) ……………..................................................... 5mL 
The final volume of RDM was prepared under sterile conditions inside the laminar flow hood. 
The B27 supplement and PSA were thawed in a 37_M7J;H87J> before the formulation of the 
medium. The components were added to a 500mL, 0.2µm bottle top filter attached atop a 500mL 
tissue culture bottle, and the medium was filter-sterilized before final usage. RDM was stored at 
_for up to 4 weeks. 
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2.1.2.4 Dispase  
The use of the enzyme Dispase (GIBCOTM, Ref. #17105-041) is recommended for passaging of 
human iPS cells. A final working concentration of 2mg/mL of dispase was prepared under sterile 
conditions inside the laminar flow chamber. 100mg of dispase was weighed and carefully added 
to a 50mL conical tube containing 50mL of DMEM/F12. The conical tube was mixed several 
times by inverting to make sure there were no floating clumps of dispase powder in the solution. 
The solution was warmed for 20 minutes in a 3_M7J;H87J><J;H J>; :?IF7I; IEBKJ?EDM7I
sufficiently warm, the solution was filter sterilized using a 50mL, 0.22µm Sterifilp® filter 
(MilliporeTM?IF7I;IEBKJ?EDM7IIJEH;:7J_for up to 2 weeks.  
 
2.1.2.5 Matrigel  
Matrigel (BD Biosciences) was used as the basement membrane matrix compound to coat 6-well 
plates for the growth of human iPS cells on them. Matrigel received from the vendor was thawed 
on ice, aliquoted, and frozen down at -_;<EH;KI;	C7JH?=;BM7I:?BKJ;:?D9EB:'' 
according to vendor specifications and 1mL of cold matrigel was used to coat 1 well of a 6-well 
plate. A 50mL solution of diluted matrigel M7IIJEH;:7J_for up to 2 weeks. 
 
2.1.2.6 Laminin 
For differentiation of human iPS cells as adherent cultures, 6-well plates were coated with 
laminin (Stemgent™, Catalog #08-0002), part of the extracellular matrix (ECM) family of 
glycoproteins. Laminin received from the vendor was stored in -_;<EH;KI;	71mL vial of 
B7C?D?DM7IJ>7M;:EL;HD?=>J7J_.E9E7JFBates, laminin was diluted with DMEM (1X) in a 
ratio of 1:50 to achieve a final concentration of 20µg/mL. Diluted laminin was added to the center 
of the well and carefully spread using the back end of a P1000 micropipette tip. The laminin was 
uniformly spread covering majority of the well area except the edges. 
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2.1.3 Thawing of Cryopreserved Human iPS Cells 
Media and supplements required: 
1) Complete mTesrTM1  
2) DMEM/F12 
3) Matrigel 
Human iPS cells were thawed and plated onto a 6-well plate (Thermo Scientific, Nunclon treated) 
that was coated with matrigel and incubated for an hour at room temperature before subsequent 
thawing of cells. The general criterion for number of vials of cells plated/ well of a 6 well plate 
was based on the equivalency of number of cryovials used to freeze down cells from a single well 
of a 6-well plate, i.e. 1 vial of cryopreserved cells made from 1 well of a 6-well plate was used to 
thaw in 1 well of a 6-well plate. Before the start of the protocol and removal of the vial of cells 
from liquid N2 IJEH7=;	7BBC;:?7M7IM;BBM7HC;:?D7_M7J;H87J>and the 6-well plate was 
prepared with matrigel. A 15ml conical tube was filled with 10mL of warm DMEM/F12. At this 
stage, the vial of human iPS cells was removed from the liquid N2 J7DA 7D: J>7M;: ?D 7 _
waterbath by shaking vigorously for 3-4 minutes. The contents of the cryovials were transferred 
into the conical tube containing the DMEM/F12 and the tube was centrifuged at 800rpm for 3 
minutes. After the centrifugation was complete, the medium from the conical tube was aspirated 
leaving the iPS cell pellet intact. Next, the liquid matrigel was aspirated from the coated tissue 
culture plate. 2mL of mTeSRTM1medium was slowly added to the coated well from the sides 
using a serological pipette. The iPS cell pellet was then resuspended in 0.5mL of mTesrTM1 
medium to dislodge the pellet and break down any bigger aggregates of cells and then transferred 
to the coated well of the 6-well plate containing 2mL of mTesrTM1. The medium containing the 
cell aggregates was poured slowly in the middle of the well with the tip of the serological pipette 
perpendicular to the well. The 6-M;BBFB7J;M7I JH7DI<;HH;: JE7_ ?D9K87JEH.>;9;BBIM;H;
9KBJKH;:7JDEHC7BF>OI?EBE=?97B9ED:?J?EDI?DI?:;J>;?D9K87JEH_	M?J>)2, and  
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humidity. Daily media changes with mTesrTM1 were performed henceforth until the 
undifferentiated colonies of human iPS cells were ready to be passaged.  
 
2.1.4 Maintenance and Passaging of Human iPS Cells 
Media and supplements required: 
1) Complete mTeSR™1 
2) DMEM/F12  
3) Dispase 
4) Matrigel  
Human iPS cells were maintained and expanded in an undifferentiated state using methods 
previously described for human pluripotent stem cells [30, 107]. iPS cells were grown on matrigel 
in mTeSR™1 for the maintenance of an undifferentiated state. The cells were passaged every 4-5 
days when the colonies approached 70- 9ED<BK;D9O. They were enzymatically lifted using 
dispase (2mg/mL) after the differentiation colonies were first manually removed. The appearance 
of spontaneous differentiation in iPS colonies was identified by the loss of its prominent phase 
bright borders and emergence of non-uniformly shaped cell types. All culture media was well 
warmed and the required number of 6-well plates coated with matrigel and incubated at room 
temperature for 1 hour before the process. 1 well of a 6-well plated of iPS cells was expanded to 1 
whole 6-well plate. Before each round of passaging, the differentiation areas were marked under 
the microscope and the colonies scraped out using a tip of the P1000 micropipette. The medium 
on the cells containing the free floating differentiated aggregates was aspirated out and 1mL of 
dispase was added to the well. The cells were incubated in dispase for 15-20 minutes at room 
temperature to allow for sufficient curling of the edges of the iPS colonies. At the end of this 
incubation, the dispase was aspirated and the cells were washed twice with 1mL of DMEM/F12 
to remove any residual dispase on the cells. Using a 10mL serological pipette, the enzymatically 
loosened iPS colonies were easily dislodged by 2-3 rigorous draws with the pipette and 
transferred to a 15mL conical tube and allowed to settle. The matrigel on the plate was aspirated 
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and 2mL of mTeSR™1 medium added to the each well from the sides. The DMEM/F12 in the 
conical was aspirated leaving the iPS cells at the bottom. The iPS cells were then resuspended in 
3mL of mTeSR™1 and a few draw and release motions were performed to break down any large 
aggregates of cells. To each well of a 6-well plate, 0.5mL of iPS cells in mTeSR™1 was added to 
the center of the well with the tip of the serological pipette perpendicular to the well. Care was 
taken to keep the iPS colonies at appropriate sizes as bigger colonies are more prone to 
differentiation and smaller colonies or single iPS cells would have less chances of survival. The 
6-M;BBFB7J;M7IJH7DI<;HH;:JE7_?D9K87JEH7D:shaken to ensure the uniform distribution of 
the cells in the well to prevent overcrowding of proliferating colonies later on. The cells were 
9KBJKH;:7JDEHC7BF>OI?EBE=?97B9ED:?J?EDI?DI?:;J>;?D9K87JEH_	M?J>)2, and 
humidity. The different stages in the passaging of human iPS cells are represented in (Figure 6). 
 
2.1.5 Differentiation of Human iPS Cells 
2.1.5.1 Neural Induction 
Media and supplements required: 
1) Complete mTeSR™1 
2) NIM 
3) Laminin coated plates 
4) RDM 
Neural differentiation and induction of human iPS cells toward an anterior neural fate was 
performed using methods previously described [30, 107]. A population of the enzymatically lifted 
iPS cell aggregates were grown in suspension in mTeSR™1 medium as embryoid bodies starting 
at day 0 and cultured in 3:1, 1:1, 1:3 mTeSR™1:NIM  medium in the next 3 days and switched 
completely to the chemically defined NIM medium at day 4. After 6-7 days of growth and 
differentiation in suspension, the embryoid bodies were induced to attach to laminin coated 6-
well plates to allow for the formation of neural cells. The neural cells were grown as adherent 
cultures for the next 10 days of differentiation. Within a few days of plating on laminin, the 
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appearance of columnar, neural tube-like cells could be observed. At day 16 of differentiation, the 
human iPS cell derived neural rosettes were mechanically lifted using a P1000 micropipette and 
grown as suspended spheres in non-adherent culture dishes in RDM. In the next 2 days, a subset 
of these spheres acquired a prominent golden ring-like structure around its borders indicative of 
the optic vesicle like appearance as in development in vivo [107]. These optic vesicle-like 
neurospheres were manually separated from other non-optic vesicle-like spheres and both 
populations of spheres grown in suspension in different dishes. The timeline for the neural 
induction of human iPS cells is explained in (Figure 7). 
 
2.1.5.2 Retinal Differentiation of Human iPS Cells 
Media and supplements required: 
1) RDM 
2) FGF, EGF, Heparin 
3) Laminin coated coverslips 
The differentiation of the human iPS cell derived optic vesicle-like or retinal neurospheres was 
carried out in RDM after they were manually separated from the non-optic vesicle-like or non-
retinal neurospheres. The differentiation of RPE was continued as adherent cultures after day 16 
until 40-50 days of differentiation in RDM. Medium changes with fresh RDM was done every 2 
days depending on the amount of cells and proliferation per well of the plate. The emergence of a 
hexagonal morphology coupled with emergence of pigmentation was used to identify RPE. The 
pigmented areas were manually microdissected using a P200 micropipette and further grown as 
adherent RPE cultures on laminin coated coverslips. The medium was supplemented with the 
mitogens fibroblast growth factor 2 (FGF2) (20ng/ml) and epidermal growth factor (EGF) 
(20ng/ml), along with 2µg/mL of heparin to allow for the proliferation of pigmented RPE cells 
for 2 weeks. Differentiation of other cell types within the retina was carried out by the culture of 
the retinal neurospheres in suspension in RDM. For RGCs and photoreceptors, the differentiation 
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was carried out until different timepoints within a range of 70 days of differentiation. The 
suspended retinal neurospheres were fed with a strict regimen of medium changes every alternate 
day with RDM and conditioned RDM from the cells in a 1:1 ratio.  The conditioned medium from 
the spheres was collected in 1.5mL eppendorf tubes and centrifuged at 2000rpm for 3 minutes 
before being combined with fresh RDM to be added to the cells to get rid of any cellular debris or 
single cells in the medium. Overgrown spheres were kept an appropriate size by regular and light 
trituration once a week.  
 
2.1.5.3 Differentiation and Passaging of Astrocytes from Human iPS Cells 
Media and supplements required: 
1) RDM 
2) EFH (20ng/mL) 
3) Laminin coated plates  
The population of human iPS cell derived non-retinal neurospheres was differentiated in RDM 
for specification towards an astrocyte cell fate. The differentiation protocol used was modified 
from methods previously described to derive astrocytes from human pluripotent stem cell sources 
[111, 112]. The non-retinal neurospheres were grown in suspension as astroshperes until 85 days 
of differentiation, supplemented with EGF/FGF/Heparin (EFH) (20ng/mL) from day 20. Medium 
changes were performed every alternate day with RDM and conditioned medium from the cells, 
in a 1:1 ratio, and EFH (20ng/ml) was added. The conditioned medium from the spheres was 
collected in 1.5mL eppendorf tubes and centrifuged at 2000rpm for 3 minutes before being 
combined with fresh RDM and EFH to be added to the cells to get rid of any cellular debris or 
single cells in the medium. At day 85, the spheres were plated down onto laminin-coated wells of 
6-well dishes and allowed to proliferate in the same media conditions. Upon confluence, the 
mixed population of post-mitotic neurons and non-post-mitotic astroglia was enriched for 
astrocytes by enzymatic passaging using accutase (2mg/mL). All media was well warmed before 
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the process and the required number of wells of a 6-well plate was coated with laminin for 4 
hours before use. Following the aspiration of media from the cells, a single wash was performed 
with RDM. 1mL of accutase was added to the cells and incubated at room temperature for 3-5 
minutes. After 5 minutes, the accutase was inactivated by equal volume of fetal bovine serum 
(FBS) and the enzymatically loose cells were dislodged with a P1000 micropipette with a couple 
of regular draws and collected in a 15 mL conical tube. The cell solution was passed through a 
70µm cell strainer (BD Falcon™, Ref. #325350) to achieve a single cell suspension. Next, the 
cell suspension was centrifuged at 2000rpm for 3 minutes. The supernatant was aspirated leaving 
the cell pellet intact. The laminin was aspirated from the 6-well plate and 1mL of RDM was 
added to the well from the side. The pellet of cells was resuspended in 1ml of RDM and added to 
the laminin-coated well. 2µl of EFH was added the well. The 6-well plate was transferred to a 
_?D9K87JEH7D:shaken to ensure the uniform distribution of the cells in the well to prevent 
overcrowding of proliferating cells. The cells were cultured at normal physiological conditions 
?DI?:;J>;?D9K87JEH_	M?J>)2	7D:humidity. The cells were passaged every 7-
10 days.  
 
For experiments measuring the doubling time and proliferation rates of astrocytes, the cells were 
counted using a hemacytometer (Fisher Scientific, Catalog #0267110) and plated at a density of 
100,000cells/well and passaged every 7 days for 4 passages starting at day 95-100 of 
differentiation.  
 
2.1.6 Freezing Human iPS Cells 
Media and supplements required: 
1) Complete mTeSR™1 
2) FBS 
3) Dimethyl Sulphoxide (DMSO)
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The cryopreservation of iPS cells was performed using methods similar to the passaging of iPS 
cells as described above. Fresh freezing medium was prepared and well warmed before the 
process. As a general rule, cells from 1 well of a 6-well plate were frozen in 1 cryovial 
(Wheaton™, Ref. #985916). The medium used to freeze down human iPS cells consisted E<
C.;-,U	  -	7D::?C;J>OBIKBFEN?:;'-) ?I>;H-9?;DJ?<?9	7J7BE=*-
100). Before the process, the differentiated colonies were marked and scraped out as described 
earlier. The cells were treated as a regular passage of iPS cells until the step of collection of the 
dislodged iPS cell aggregates in a 15mL conical tube. At this point, the cell suspension was 
centrifuged at 800rpm for 1 minute. The supernatant was discarded and the iPS cell pellet was 
resuspended in freezing medium. The cell suspension was added to a 2mL cryovial and placed in 
7D?IEFHEF7DEB_<H;;P?D=9EDJ7?D;H(7B=;D;U	7J7BE=-0001) to achieve for controlled 
cooling rates of approximately -_C?DKJ; .>; <H;;P?D= container was placed at -_
overnight. The cryovials were transferred to liquid N2 storage, the next day. 
 
2.2 Immunocytochemistry (ICC) 
Sterile coverslips were placed into sterile 4-well or 24-well plates. The coverslips were 
aseptically coated with 0.1mg/mL of Poly-D-Ornithine followed by 3 washes with sterile water 
and kept under sterile conditions at room temperatures for overnight. Poly-D-Ornithine coated 
plates were ready to use for ICC experiments the next day. ICC analysis was carried out by 
methods described previously [30]. For ICC procedures, the polyornithine-coated coverslips were 
further coated with laminin and incubated for 4 hours before use.  After the incubation period, 
neurospheres were plated onto polyornithine- and laminin-coated coverslips overnight to allow 
for attachment. The next day, 9;BBI M;H; ;?J>;H <?N;: ?D  F7H7<EHC7B:;>O:; B;9JHED
Microscopy Sciences, Catalog #15714S) or continued in culture for a few days in the required 
growth medium. For fixation purposes, ICC plates were brought into the fume hood and 
29 
 
	  
	  
?D9K87J;: ?D  F7H7<EHC7B:;>O:; <EH C?DKJ;I 7J HEEC J;CF;H7JKH;<J;H C?DKJ;I	 J>;
paraformaldehyde was aspirated and the coverslips were washed 3 times in 1X phosphate buffer 
I7B?D; *- ;BBI M;H; J>;D F;HC;78?B?P;: ?D  .H?JED 2-100 (Fisher Scientific, Ref. 
#BP151-100). This was followed by a single wash with 1X PBS and a 1 >EKH?D9K87J?ED?D
donkey serum. Next, cells were immunostained using primary antibodies listed in (Table 1), in 
.H?JED2-7D::EDA;OI;HKC Coverslips treated with primary antibodies were left in 
overnight 7J _  .>; <EBBEM?D= :7O	 J>; FH?C7HO 7DJ?8E:O IEBKJ?EDI M;H; H;Coved and the 
coverslips were washed 3 times with 1X PBS followed by another round of incubation with 
donkey serum for 10 minutes. The cells were labeled and visualized with either Alexafluor 350, 
488, 584 or Cy3-conjugated secondary antibodies, and nuclei were counterstained with 4',6-
diamidino-2-F>;DOB?D:EB; *# .>; I;9ED:7HO 7DJ?8E:?;I 7D: *# M;H; :?BKJ;: ?D 
Triton X- 7D:  :EDA;O I;HKC 8;<EH; KI; ;BBI M;H; ?D9K87J;: M?J> J>; I;9ED:7HO
antibodies for an hour at room temperature followed by 3 washes with 1X PBS. Finally, the 
coverslips were mounted using Aqua Poly Mount (Polysciences, Inc™, Catalog #18606) on glass 
slides. After allowing time for mounting, images were obtained on a Leica 5500 upright 
epifluorescence microscope. 
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2.3 Microscopy 
 
2.3.1 Brightfield Microscopy 
Images for iPS cells in its undifferentiated state and stepwise differentiation into anterior neural 
and retinal lineages were obtained using a Nikon Eclipse TS100 Brightfield Microscope. Late 
stages of differentiation into retinal cell types were easily analyzed for RPE with its characteristic 
hexagonal morphology and brownish yellow pigmentation with a visible apical-basal transport of 
proteins in the brightfield. Images for neuroretinal proliferation for other mature retinal cell types 
were obtained but identification of individual retinal cell types in brightfield was not possible due 
to lack of scientific literature for the same. Similarly, astrocytes obtained in culture at different 
timepoints of differentiation were identified with their characteristic stellate shaped cell bodies 
and extensive outward processes. The progression of differentiation of astrocytes was observed 
until 150 days of differentiation in culture. All brightfield images for the different experiments 
were taken at both 4X and 20X. 
 
2.3.2 Fluorescence Microscopy 
The analysis of characteristic protein expression at different developmental stages from 
pluripotency to the derivation of mature retinal cell types was performed by ICC with subsequent 
analysis using a Leica 5500 upright epifluorescence microscope. Three different channels 
identifying the labeled proteins were used to combine co-expression analysis for different ICC 
experiments. Further image processing and enhancement was performed using the 3-dimensional 
deconvolution tool on the computer. The deconvolution tool was used to bring into focus images 
whose 3-dimensional and complex arrangement of cells resulted in the population of cells to emit 
light rendering the image as a whole, out of focus. As a part of the 3-dimensional convolution 
tool, images were taken at different focal planes (also called as z-stacking) and corrected for 
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blurriness and out of focus arrangements of cells. A final image with the best possible contrast 
and resolution was obtained from the set of z-stacks used to deconstruct the image initially. All 
images for the different experiments were taken at 3 magnifications, 10X, 20X, and 40X. 
 
2.4 Polymerase Chain Reaction (PCR) 
 
2.4.1 Reverse Transcription-PCR (RT-PCR) 
Total RNA was isolated from cells at different stages of differentiation using the RNeasy® Mini 
Kit (Qiagen, Catalog #746106) or the Arcturus® PicoPure® RNA isolation kit (Applied 
Biosystems, Catalog #12204-01). The RNA was treated with DNase I to remove any genomic 
DNA contamination. 1-2µg of RNA was reverse transcribed to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad, Catalog #170-8891). The final cDNA volume was diluted in ratios of 1:10 
in RNA quality water and could be stored for long term use at -_.>;9(M7I7CFB?<?;:
by PCR using the GoTaq PCR master mix (Promega) and primers for specific experiments, listed 
in (Table 2). The cycler conditions used for RT-*,M;H; 7I <EBBEMI FH;>;7J;: B?: 7J _	
?D?J?7B :;D7JKH7J?ED 7J _ <EH  C?DKJ;I	  9O9B;I E< :;D7JKH7J?ED 7J _ <EH  I;9ED:I	
7DD;7B?D=7J_<EHI;9ED:I	7D:;NJ;DI?ED7J_<EHC?DKJ;	<?D7B;NJ;DI?ED7J_<EH
C?DKJ;I	7D:7<?D7B>EB:7J_ EH;79>HKD	!*"M7IKI;:7I79EDJHEB7D:HKDKI?D=
the same program for 20 cycles. All experiments were run for the same number of cycles unless 
EJ>;HM?I; ?D:?97J;: -K8I;GK;DJ *, FHE:K9JI M;H; HKD ED  7=7HEI; =;BI JE 7D7BOP; =;D;
patterns. 
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2.4.2 Quantitative RT-PCR (qRT-PCR) 
For quantitative RT-PCR, RNA was isolated and cDNA synthesized as described in the previous 
section. cDNA was amplified using the SYBR green master mix (Applied Biosystems, Lot 
#4309155) and analyzed by the 7300 RT detection software (Applied Biosystems). The primers 
used are listed in (Table 3). A final reaction volume of 20µl was used for all experiments. The 
9O9B;H9ED:?J?EDIKI;:<EH7BBG*,;NF;H?C;DJIM;H;?D?J?7B:;D7JKH7J?ED7J_<EHC?DKJ;I	
9O9B;IE<:;D7JKH7J?ED7J_<EHI;9ED:I	7DD;7B?D=7J_<EHseconds, and extension 
7J_<EHC?DKJ;	<?D7B;NJ;DI?ED7J_<EHC?DKJ;IDEJ;CFB7J;9EDJHEB7D:7ß-Actin 
internal control were used for all experiments. All qPCR reactions were run at 40 cycles. The 
change in gene expression levels was measured using the 2-ΔΔCt method, where Ct was the 
crossing threshold fluorescence value. ΔCt was measured as the Ct value of the target gene minus 
the Ct value for ß-Actin. ΔΔCt was equal to the ΔCt value of sample minus the ΔCt value of 
control.  
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
	  
	  
2.5 Statistical Analysis 
For quantification of ICC data, cells immunolabeled with a particular marker were counted and 
compared to total number of cells in the view field as identified by the DNA stain DAPI. At least 
2 representative fields from 2 coverslips were photographed in each of 3 separate experiments 
and individual cell counts were made using the ImageJ software (National Institutes of Health). 
The measurements of cell sizes and neurite lengths of retinal cells were done using quantification 
tools in the Leica 5500 upright epifluorescence microscope. Cell body areas were demarcated and 
measured in square microns and the lengths of RGC and photoreceptor neurites were measured in 
micron meters. All statistical analysis was conducted using the GraphPad PRISM version 6.0 
(GraphPad Software Inc.). The statistical significance of differences was determined using the 
unpaired t-J;IJ  FHE878?B?JO L7BK; E< B;II J>7D  M7I 9EDI?:;H;: JE 8; I?=D?<?97DJ BB
experiments were conducted in triplicate unless otherwise stated. All values were expressed as 
means ± standard error. 
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CHAPTER 3 – ESTABLISHMENT OF AN IN VITRO SYSTEM OF USHER 
 
SYNDROME USING HUMAN IPS CELLS 
 
 
 
3.1 Introduction 
 
Usher syndrome is the most commonly inherited disorder affecting both vision and hearing, with 
or without vestibular dysfunction. It is an autosomal recessive disease which means it can affect 
males and females with equal frequency. A person has to inherit the altered copy of the affected 
gene from both parents to be diagnosed with this disease. A person inheriting only one copy of 
the mutated gene is an unaffected carrier for future generations. Usher syndrome patients suffer 
from sensorineural hearing impairment and retinal degeneration resulting in gradual to eventual 
loss of vision. Its symptoms include congenital, bilateral deafness and loss of vision due to 
retinitis pigmentosa (RP). The loss of visual function in Usher syndrome starts with the loss of 
night vision, progressing to the loss of photoreceptors from the periphery to the macula resulting 
in tunnel vision, and finally to complete blindness [113]. Hearing loss in Usher syndrome is due 
to degenerating nerve cells in the cochlea, the sound-transmitting structure of the inner ear. Usher 
syndrome can be clinically divided into 3 subtypes, Usher syndrome type I, II, and III, depending 
on the onset, severity, and progression of its symptoms. Usher syndrome patients also experience 
balance issues from birth in the type I form of the disease whereas the vestibular function is 
normal or near normal in types II and III. Besides the clinical differences, Usher syndrome is also 
characterized by its genetic heterogeneity. A total of 12 genetic loci and 10 genes have been 
identified to be associated with this disease [50, 51, 114]. Usher syndrome type I is divided 
further into the 6 subtypes: 1B, 1C, 1D, 1F, 1G, 1H depending 
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on mutations in the following genes, MY07A, USH1C, CDH23, PCDH15, SANS, and USH1H 
respectively [114, 115]. Usher syndrome type II is divided into at least 3 subtypes: 2A, 2C, 2D, 
affected by mutations in the genes, USH2A, VLGR1A, WHRN respectively, and type III has been 
associated with mutations in one gene CLRN1 [115, 116]. Usher Syndrome is currently incurable, 
and the development of future therapeutic approaches requires further insight into disease 
mechanisms and progression. Current treatment strategies involve the use of educational and 
vocational programs to manage symptoms following early identification of the disease. Ongoing 
research in this disease involves the identification of more causative genes and its different 
variations. Identification of all genes is crucial to improved genetic counseling and quick 
diagnosis of the disease. Application of gene correction and pharmacological intervention 
strategies are also being used to slow the progression of the symptoms associated with the 
disease.  
 
This study aims to provide a novel platform to further understand the genetic complications 
associated with Usher syndrome. More specifically, this study addresses the pathophysiology of 
visual degeneration in Usher syndrome patients associated with RP. RP as stated is characterized 
by the degeneration of photoreceptors, from the periphery to the macula, progressing from night-
blindness in Usher patients to complete loss of vision. Taking advantage of the “disease-in-a-
dish” concept, this study aims to characterize and establish the potential of an Usher syndrome 
patient specific iPS cell line to differentiate in vitro towards a retinal lineage progressing through 
all the major stages of normal retinal development. The use of iPS cell technology to model the 
degenerative progression of Usher syndrome provides a robust approach that employs the use of a 
more practical human model to study the different aspects of the disease. The eventual goal of 
this study is to provide a time feasible and a cost effective way to derive patient-specific affected 
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retinal cell types, the diseased photoreceptors, in large numbers, which could then be used for 
further downstream experiments to further disease development and treatment.  
 
3.2 Results 
 
 
3.2.1 Establishment of Pluripotency of Usher Syndrome iPS Cells 
 
To establish the pluripotent and unspecialized nature of the type III Usher syndrome patient 
specific iPS cell line, following numerous passages in vitro, the Usher syndrome iPS cells were 
analyzed for all pluripotency associated characteristics as examined by ICC and RT-PCR 
analysis. ICC analysis revealed that Usher syndrome iPS cells maintained expression of 
pluripotency associated proteins, OCT4, SOX2, and NANOG (Figure 8: A,C,E). These 3 factors 
including, along with LIN28, were initially used to reprogram the skin cells of a type III Usher 
syndrome patient using lentivirus. ICC experiments also confirmed the expression of the 
endogenously activated pluripotency-related cell genes/ surface antigens such as TRA-1-60, 
TRA-1-81, and SSEA-4 (Figure 8: B,D,F). The onset of expression of these endogenous 
pluripotency genes besides the ones used for reprogramming was evidence for the completely 
reprogrammed nature of the Usher iPS cell line. In brightfield microscopy, the Usher syndrome 
iPS colonies exhibited typical pluripotent morphologies including cells that were tightly packed 
together with well-defined and phase bright edges (Figure 9). Larger colonies appeared to be 
somewhat 3-dimensional when viewed under the microscope and differences between an 
undifferentiated and differentiated colony were clearly visible during spontaneous differentiation 
events with the differentiated iPS cells easily identifiable by their non-uniform shape and lack of 
well-defined edges. Furthermore, RT-PCR results confirmed the expression of pluripotency-
related genes, OCT4, NANOG, and SOX2 and further established the undifferentiated nature of 
the cell line by confirming the lack of expression of markers associated with the 3 germ layers of 
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development, including, ALPHA-FETOPROTEIN for endoderm, BRACHYURY for mesoderm, 
and PAX6 for ectoderm (Figure 10). 
 
3.2.2 Anterior Neural and Eye Field Specification from Usher Syndrome iPS Cells 
 
The first stage in the stepwise differentiation of the Usher syndrome iPS cell line to a retinal 
lineage was the derivation of an anterior neuroepithelial cell fate which gives rise to the optic 
vesicles in vivo. As described in the methods section, iPS cells were grown as free floating 
embryoid bodies and transitioned into a chemically defined medium, NIM, for neural induction. 
The free floating embryoid bodies were plated onto laminin coated coverslips after 6-7 days of 
differentiation and allowed to proliferate as neural rosettes until 10 days in culture before being 
<?N;:?DF7H7<EHC7B:;>O:;<EH#7D7BOI?I#;NF;H?C;DJIH;L;7B;:J>;BEIIE<;NFH;II?ED
of pluripotency associated factors OCT4 and NANOG followed by the increase of transcriptional 
expression of factors associated with general neural induction and anterior neural development, 
including PAX6, SOX1, OTX2, and LHX2 (Figure 11). Furthermore, the appearance of the 
expression of neurodevelopmental transcription factors was associated with the formation of 
neural rosette like structures, reminiscent of neural tube formations in vivo (Figure 11). The 
proliferation of early neural cells as rosettes were was further confirmed as seen under brightfield 
microscopy (Figure 12). To further confirm the anterior nature of neural progenitor cells derived 
from the Usher syndrome iPS cell line, RNA samples were taken after 10 days of differentiation 
to be analyzed by RT-PCR analysis. RT-PCR results confirmed the accumulation of transcripts 
encoding numerous early neurodevelopmental transcription factors, PAX6, SOX1, OTX2, and 
LHX2. Also, by day 10, RT-PCR revealed expression of early eye development marked by the 
accumulation of transcripts encoding eye field transcription factors (EFTFs), RAX, SIX3, SIX6, 
and NR2E1 (TLL) (Figure 13). The committed nature of differentiation of the Usher syndrome 
iPS cell line was indicated by the expected decrease in the level of the pluripotency factors OCT4 
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and NANOG. RT-PCR of the early neural factor PAX6 revealed a doublet, indicating the presence 
of the alternately spliced isoforms of the PAX6 gene, the +5a and -5a isoforms. 
 
3.2.3 Derivation of Retinal Progenitor Cells from Usher Syndrome iPS Cells 
 
After establishing a primitive neural fate of the human iPS cell line, this study looked to 
characterize the Usher syndrome iPS line at later stages of differentiation. The free floating 
embryoid bodies were grown as adherent cultures in NIM until day 16 of differentiation. At this 
stage, the rosette containing colonies were mechanically lifted into RDM for the formation of 
neurospheres in suspension. Following 2 days of further induction, the suspended aggregates of 
cells formed two distinct sets of neurospheres when viewed in brightfield microscopy. A subset 
of spheres composed of an outer layer of phase bright cells, indicative of an optic vesicle like 
morphology whereas the other group contained spheres with a near uniform distribution of cells 
in each aggregate and with a more spherical looking morphology, at times with rosette 
internalization [107] (Figure 14). Cell aggregates possessing characteristics of both kinds of 
spheres were excluded from further differentiation analysis. The optic vesicle-like spheres were 
manually picked out and allowed to further differentiate in suspension in RDM. Following 20 
total days of differentiation, these manually picked retinal neurospheres were analyzed for their 
RNA and protein expression patterns. ICC revealed that a subset of cells exhibited numerous 
characteristics of retinal development, including the presence of key transcription factors 
including the definitive retinal progenitor marker CHX10, and other early retina associated 
transcription factors SIX6, LHX2 and PAX6 (Figure 15). RT-PCR analysis further confirmed the 
presence of the retinal progenitor transcriptional markers including the critical retinal progenitor 
gene RAX, and other genes, CHX10, LHX2, OTX2, and PAX6 (Figure 16). The development of 
retinal progenitor cells after 20 days of iPS cell differentiation was analogous to the origin of 
optic vesicles in normal human development. 
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3.2.4 Mature Neural Specification from Usher Syndrome iPS Cells 
 
After 30 days of differentiation, the development of more mature neuronal characteristics was 
assessed in culture. Neural, non-retinal cells mechanically lifted at day 16 were grown as spheres 
in suspension in RDM until day 28 before being plated onto laminin coated polyornithine 
9EL;HIB?FI 7D: <?N;: ?D  F7H7<EHC7B:;>O:; <EH # 7D7BOI?I # H;IKBJI 9ED<?HC;: J>7J 7
subset of cells co-expressed both the master neuroectoderm nuclear marker PAX6 and the 
cytoskeletal marker for newly committed neurons, ß-III TUBULIN (Figure 17: A). Emergences 
of tubulin expression after 30 days of differentiation were good indication of regular maturation 
of neuronal cell types from the iPS cells. Further evidence of neural characteristics was observed 
by the co-expression of another set of early and mature neuronal specific factors, OTX2 and the 
microtubule associated protein MAP2 respectively. MAP2 proteins are associated with the mature 
neuronal cytoskeleton in the dendrites and the cell body. ICC analysis confirmed the expression 
of OTX2 and MAP2 in a subset of neural progenitor cells indicating a mixed population of 
progenitor and mature neurons (Figure 17: B). The evidence of neural morphologies in brightfield 
microscopy revealed the formation of rosettes in the neurospheres after almost 30 days of 
differentiation. These spheres once plated and given time to proliferate produced neuronal 
colonies with individually identifiable cells with its characteristic axon like processes (Figure 18). 
 
 
 
 
 
 
 
40 
 
	  
	  
3.2.5 Differentiation of Mature Retinal Cell Types 
 
3.2.5.1 Retinal Pigment Epithelium (RPE) 
The ability of the Usher iPS cell line to differentiate into mature retinal cell types was established 
at later time points in the retinal differentiation protocol. Consistent with vertebrate retinogenesis, 
the RPE was the first retinal cell type to be observed in culture. Early anterior neural rosettes after 
16 days of differentiation were grown in RDM as adherent cultures until day 40-50 when the first 
definitive characteristics of RPE like cells were observed. Colonies of cells organized themselves 
in distinct patches of hexagonal shaped epithelial-like cells with a characteristic pigmentation 
pattern that was easily identifiable in brightfield microscopy. The levels of pigmentation 
increased over a period of next 10 days of differentiation and were maintained at even higher 
levels at later time points in culture (Figure 19: A,B). For protein analysis of these RPE-like cells, 
the pigmented areas were carefully microdissected and allowed to proliferate on laminin coated 
coverslips in the presence of RDM and mitogens, EGF and FGF, along with heparin. Following a 
week of treatment with mitogens, the cells were then grown as typical monolayers in the absence 
of the growth factors for an additional 1 week. After 60 days of differentiation, the cells were 
<?N;:?DF7H7<EHC7B:;>O:;7D:7D7BOP;:<EHJ>;?HFHEJ;?D;NFH;II?EDFHE<?B;I#CCKDEIJ7?D?D=
revealed co-expression of the RPE associated gene OTX2 along with the RPE-associated tight 
junction protein ZO-1 (Figure 20: A-C). The cells also contained more mature RPE-related apical 
proteins such as EZRIN and basolateral proteins such as BESTROPHIN (Figure 20: D-F). ICC 
analysis further revealed a clear cobblestone RPE-like morphology for these cells derived from 
human iPS cells. To identify the level of transcriptional expression of RPE-related genes, the 
microdissected pigmented RPE-like cells were analyzed by RT-PCR. RT-PCR experiments 
further confirmed the transcriptional expression of RPE associated genes including the RPE 
progenitor marker MITF, and mature markers including RPE secreted factors like PEDF, 
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important visual cycle proteins, RPE65, CRALBP, and transcript levels of other RPE genes 
confirmed by ICC, OTX2, ZO-1, EZRIN, and BESTROPHIN (Figure 21). 
  
3.2.5.2 Neural Retina 
The derivation of RPE was followed by the specification of the neural retina from the iPS cells at 
even later time points of differentiation. The study aimed to establish the potential of the Usher 
syndrome patient-specific iPS cell line to differentiate into mature retinal cell types including the 
most important for this study, photoreceptors. Usher syndrome iPS cell derived retinal progenitor 
cells were grown as retinal neurospheres for a period of 70 days in RDM growth medium. The 
neurospheres were kept at an appropriate size by regular and light trituration of overgrown 
spheres and cultured in fresh RDM every alternate day. After 70 days of differentiation, the 
retinal neurospheres were treated accordingly for analysis of their gene and protein expression 
characteristics. RT-PCR analysis revealed presence of CHX10 and CRX transcripts, further 
highlighting the progenitor stage of these retinal cell types (Figure 22). RGCs and cone 
photoreceptors are among the very first neuroretinal cell types to be derived in retinal 
development [15]. The emergence of RGCs was studied using ICC analysis after 70 days of 
differentiation. ICC results revealed a population of cells positive for the RGC specific 
transcription factor in the retina BRN3 that identifies all 3 isoforms of the gene, BRN3A, 
BRN3B, and BRN3C. Directed differentiation of RGCs was confirmed by translational co-
expression of BRN3 and another RGC-specific protein in the retina, ISLET1 (Figure 23). 
Populations expressing BRN3 and ISLET1 alone might be indicative of possibly different types 
and early stage RGCs found in the retina. Immunostaining also revealed a subset of cells 
expressing the cone and rod photoreceptor-specific precursor transcription factor CRX indicative 
of the acquisition of a mature retinal phenotype. Among the total population of cells, a group of 
CRX positive cells also expressed the mature phototransduction protein for cone and rod 
42 
 
	  
	  
photoreceptors specification, RECOVERIN indicating the stepwise conversion from an immature 
to mature photoreceptor cell fate (Figure 24).  Population of cells expressing CRX and 
RECOVERIN are further evidence of the different stages of development and maturation of the 
photoreceptors from the human iPS cells. 
 
3.3 Discussion and Future Studies 
One of the major limitations when it comes to studying disease progression in a patient is the 
limited accessibility to patient tissue material among other technical and ethical problems. The 
advent of iPS cell technology circumvents such problems by establishing patient cells in a 
laboratory dish which harbor the genetic mutations that caused or facilitated disease onset and 
development [80]. The use of patient specific iPS cells provides an unlimited supply of diseased 
cells to address issues like genetic contributions to the disease and provides means for gene 
correction and pharmacological strategies to potentially cure it. 
 
This study aims to achieve similar goals for the most commonly inherited deaf-blindness 
disorder, Usher Syndrome. The study provides the first evidence of neural and retinal 
differentiation of iPS cells derived from an Usher syndrome patient. The differentiation of mature 
retinal cell types was chronologically analogous to normal development in the human retina. The 
results demonstrate the proof-of-principle study that affected cell types can be generated from 
Usher syndrome patient specific iPS cells. This study provides a novel platform for future in vitro 
disease modeling of this disorder, which could lead to further insights into its neurogenetic 
abnormalities. Current studies in Usher syndrome are trying to identify all genetic contributors 
and variations that lead to combined symptoms of hearing and vision loss. An in vitro system like 
the one described in this study provides a feasible time frame in which we can derive the affected 
photoreceptors bearing the DNA signature of the disease. Qualitative analysis of iPS 
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differentiation to mature retinal cell types indicates a robust potential of the Usher iPS cell line to 
yield a neural retina phenotype in good quantity.  
 
In this study, the pluripotency of the Usher iPS cells is established using molecular and 
morphological characteristics as described in previous studies [70, 82]. The maintenance of 
pluripotency is indicated by the endogenous onset of expression of surface molecules including 
TRA-1-61, TRA-1-81, and SSEA-4. The genetically reprogrammed ES cell like and unbiased 
nature of the Usher iPS cell line is important for the recapitulation of time wise directed 
differentiation in vitro. The study establishes a step wise differentiation of the Usher syndrome 
iPS cell line from onset of early anterior neural characteristics to the future retinal specification at 
optic vesicle stage after 18 days of differentiation [107]. The maturation of neural and retinal 
phenotype progresses in accordance with the in vivo vertebrate development. Emergence of 
mature retinal cell types was identified by expressions of characteristic transcription factors and 
proteins associated with each somatic cell type. An efficient output of the disease cell type was 
achieved within an attainable and time period of 70 days.  
 
Overall, this study established a novel platform to further delve into the origins of the disease and 
for future studies of in vitro disease modeling, as these cells can be utilized as a tool for the study 
of disease progression, with applications for future cell replacement and drug screening studies. 
Establishment of a source of photoreceptors from disease patients provides the potential for gene 
correction and cellular therapy in personalized medicine strategies. Efforts to use iPS cell derived 
diseased cells for gene replacement and drug screening strategies have already been initiated in 
other neurodegenerative disorders including Amyotrophic Lateral Sclerosis (ALS) and cardiac 
disorders like the Long QT Syndrome [117, 118]. The use of such a system is highly beneficial to 
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understand the neurogenetic complexities of the Usher syndrome and subsequently devise 
experiments to produce treatments for this currently incurable disorder. 
 
In future studies, it will be warranted to quantify the yield of retinal progenitors and mature 
retinal cells from this cell line and compare the numbers to the cells derived from iPS cells taken 
from an isogenic carrier control and/ or a completely healthy individual. The derivation of retinal 
characteristics among these cell lines would provide for an interesting criterion to assess the 
significance of the diseased state. This study defines the onset of differentiation of photoreceptors 
but mimicking the disease phenotype and identifying old and new mutations associated with the 
disease are future directions this study envisages. Prolonged differentiation of the photoreceptors 
would be an ideal place to start for a comparative analysis in disease development and 
progression as indicated by Takahashi and colleagues in modeling the retinal disease of RP [49]. 
The short terms goals of this study is to provide a novel in vitro system to model the visual loss 
progression in Usher syndrome whereas long term applications include utilizing the diseased cell 
types for gene correction, cell replacement, and drug screening experiments to provide an overall 
data set of consensus information and potential treatment alternatives in personalized medicine 
for this disease.  
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CHAPTER 4 – DIFFERENTIATION AND CHARACTERIZATION OF AFFECTED CELL 
TYPES IN GLAUCOMA USING HUMAN IPS CELLS 
 
4.1 Introduction 
Glaucoma is the leading cause of age-related optic neuropathy in humans. It is characterized by 
the abnormal rise in intraocular pressure leading to the loss of RGC cell bodies and degeneration 
of its axons leading to complete remodeling of the ONH, especially at the level of the laminar 
cibrosa through which the optic nerve leaves the eye. As stated earlier, glaucoma is clinically 
divided into 2 main subtypes. The milder “open-angle glaucoma” is characterized by an increased 
ratio of optic cup to disk with a slow progressive loss of vision. The second subtype is the 
“closed-angle glaucoma”, which has a more acute onset with higher intraocular pressures with 
diagnosable physical symptoms including dilated pupils, a clouded cornea, and red eye. However, 
a crucial element in the pathophysiology of all forms of glaucoma is the loss of RGCs, the output 
projection neurons of the retina that make connections with different regions of the brain for 
processing of visual information. Another cell type recently associated with glaucoma is the 
retinal astrocytes, the dominant glial support of the otherwise non-myelinated RGC axons. 
Retinal astrocytes are not present at the somas of ganglion cells, and even in areas of retina in 
which they are numerous, they are sharply confined to the layer of ganglion cell axons. 
Astrocytes at the ONH are responsible for providing cellular support to RGCs and synthesizing 
extracellular molecules. It is suggested that retinal astrocytes with its vasculature are migratory 
and enter the developing retina from the brain at the optic nerve head (ONH) [119]. They have 
been associated with glaucomatous neurodegeneration, although the direct or indirect role for 
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these cells in disease is still under investigation. A majority of ongoing studies in the field of 
glaucoma research have strived to identify better ways to diagnose and subsequently characterize 
and manage the disease. There is a marked lack of studies aimed at another aspect of disease 
intervention, cell therapy. It is very well known that the reason underlying visual loss in 
glaucoma is the degeneration of RGCs and roles of astrocytes in ONH remodeling. Since not all 
cases of glaucoma are related to established genetic causes of this disease, more work needs to be 
done to identify ways to recapitulate disease progression and establish ways to derive its affected 
cell types in the laboratory.  
 
This study is aimed at achieving the directed differentiation and characterization of the somatic 
cell types associated with glaucoma using human induced pluripotent stem cells. Directed 
differentiation of several somatic cell types from human iPS cells have been successfully 
achieved with great implications for disease modeling and cell replacement strategies. RGCs have 
proven to be a complex cell type to be derived in the laboratory dish owing to different reasons 
including lack of reliable markers and complex morphologies. In humans, RGCs can be divided 
into several types depending on their molecular and morphological characteristics including the 
human specific Midget RGCs (P cells), Parasol RGCs (M cells), Bistratified RGCs (K cells),  and 
photosensitive RGCs [120, 121]. Astrocytes in general have been difficult to derive from human 
pluripotent cells. This study aims to provide ways to derive and characterize these cell types using 
human iPS cells in an achievable and pragmatic time frame. Cell therapy may be a potential way 
to restore vision in glaucoma and one of the first steps of attaining that goal would be to devise in 
vitro protocols to produce, characterize, and enhance the yield of the clinically relevant cell types 
associated with this disease. With no current cure for this disease, its progression can be slowed 
down if detected early. However, studies aimed at preventing the loss of RGCs and ONH 
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architecture are more clinically relevant in terms of providing a definitive solution to this 
devastating disease that affects millions all around the world.  
 
4.2 Results 
 
4.2.1 Differentiation of RGC Neurons from Human iPS Cells 
Using lines of human iPS cells including the Usher iPS cell line and the TIPS-5 iPS cell line, and 
building upon the preliminary data for the differentiation of RGCs from human iPS cells, this 
study further characterized both molecularly and physically, the yield and specification of RGCs 
attained after as early as 40 days of differentiation, an expected timepoint for in vitro RGCs 
specification from human iPS cells, according to recent literature and the timeline of 
retinogenesis [122]. The optic vesicle-like neurospheres manually separated after 18 days of 
differentiation and grown as retinal progenitor cells in suspension until day 40, with a specific 
regimen of medium changes every alternate day with 1:1 RDM: Conditioned RDM and a regular 
light trituration of overgrown spheres to keep at an appropriate size. At day 39, the spheres were 
plated onto laminin coated polyornithine coverslips for ICC analysis. BRN3 was used as the 
“master transcription factors” for identification of RGCs given its highly specific expression in 
the retina in early and mature RGCs. After 40 days of differentiation, ICC analysis revealed a 
subset of BRN3 positive cells that co-expressed the pro-neural cytoskeletal marker, ß-III 
TUBULIN, identifying the dendrites, cell body, and axons of BRN3 positive cells (Figure 25: A). 
The neuronal nature of the RGCs was further characterized by ICC analysis of the RGC specific 
BRN3 transcription factors and the neuronal axon marker, TAU. After 40 days of differentiation a 
subset of neurospheres co-expressed the BRN3 and TAU proteins providing for the efficient 
identification of RGC neurons (Figure 25: B). Analysis at higher magnifications revealed an 
elongated axonal morphology for the RGCs as would be expected since these cell types 
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eventually form the optic nerve making its way to the different areas of the brain. This qualitative 
identification of RGC neurons formed the basis for further morphological quantification of RGC 
axons in future experiments. 
 
4.2.2 Further Characterization of RGCs 
In an effort to further characterize the sub-population of retinal progenitor cell-derived RGCs, 
ICC analysis was used to identify expression patterns of other RGC specific transcription factors. 
The RGCs derived in culture were further specified by utilizing the expression and co-expression 
of markers associated with early and late ontogeny of RGCs in vivo. Retinal progenitor spheres 
were plated onto laminin coated polyornithine coverslips after 39 days in culture and fixed the 
IK8I;GK;DJ :7O ?D  F7H7<EHmaldehyde for ICC analysis. After 40 days of differentiation, a 
subset of retinal progenitor cells were double positive for the RGCs specific proteins BRN3 and 
ISLET1 (Figure 26: A). Although ISLET1 has been recently shown to also be expressed in some 
progenitor cells in the retina, the co-expression with BRN3 proteins is a definitive indication of 
the successful derivation of RGCs in culture. The study also looked at the expression of PAX6, a 
marker for neural/retinal progenitor cells, and is restricted in the retina to mature ganglion cells 
and interneurons such as amacrine cells. ICC analysis revealed that almost all BRN3 expressing 
cells co-expressed PAX6 with populations of cells that expressed either only BRN3 or PAX6, 
indicative of the retinal progenitor nature of cells including the onset of RGCs markers, given that 
it is the first neuroretinal cell type to be derived in development (Figure 26: B).   
 
4.2.3 Molecular and Morphological Quantification of RGCs 
After establishing a qualitative setup to identify the derivation of RGCs from human iPS cells, 
this study looked to quantify the yield of RGCs and take advantage of some morphological 
differences between RGCs and other neuroretinal cell types to further characterize this cell type. 
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It has been known that RGCs exist in different morphological forms in the human retina. These 
can be divided on the basis of dendritic forms, extent of cell body and dendritic sizes, and 
stratification levels of RGCs in the IPL [123]. Pioneering work by Cajal described in his 1892 
book, The Structure of the Retina, described the Golgi staining of these ganglion cells as a way to 
identify the different subtypes. Since then around 18 different types of RGCs have been identified 
in the human retina with the parasol, midget, and bistratified RGCs being specific only in the 
primate retina. Other types have also been seen to be present in other vertebrates like the cat. 
Another physical feature that distinguishes RGCs from other retinal cell types is its ability to 
project to long distances in areas of the brain on account of its larger diameter and longer axons 
[123]. Axonal lengths associated with RGCs are quite significantly longer compared to other 
interneurons and photoreceptor segments.    
 
4.2.3.1 Quantification of Yield of RGCs 
Firstly, the study quantified the yield of RGCs among a mixed population of neuroretinal cell 
types by counting individual cells in the co-expression pattern of RGC specific proteins from 
experiments described previously. Retinal progenitor cells were analyzed by ICC after 40 days of 
differentiation. As stated, at least 2 representative fields from different coverslips in a set of 3 
replicable experiments was photographed and counted. The publicly available image processing 
software, Image J, developed at the National Institutes of Health was used for image analysis and 
quantifying cell counts. Cell counts were taken for the subset of progenitor cells positive for 
BRN3 and ISLET1 co-expression and the yield of RGCs calculated (Figure 27). Individual 
expressions of BRN3 and ISLET1 were counted in addition to the cells expressing both. This data 
was quantified over a value of all nuclear labeled DAPI positive cells in the area. Approximately 
 - E<  E< J>; 9;BBIM;H; FEI?J?L; for the expression of BRN3, specific to the 
,!I	 M>;H;7I 7HEKD:  - E<  E< J>; 9;BBI ;NFH;II;: ISLET1, a broad 
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transcription factor expressed by the RGCs and retinal progenitors. However, a more definitive 
statistic for the number of RGCs d;H?L;:M7IJ>7J7HEKD:E<J>;JEJ7BFEFKB7J?EDE<9;BBI
that expressed both BRN3 and ISLET1. This quantification of co-expression provides further 
evidence for the efficient derivation of RGCs from human iPS cells. A similar count for BRN3 
positive cells was also observed for ICC experiments with BRN3 and PAX6. 
 
4.2.3.2 Quantification of Cell Sizes of RGCs 
Taking advantage of the larger cell bodies of RGCs compared to other retinal neurons, this study 
measured the area of RGCs and compared it to other retinal neurons derived in the process. To 
measure difference in cell body sizes the study again used the master transcription factor BRN3 
as a basis for identifying the population of RGCs. BRN3 was used in combination with the neural 
cytoskeletal marker ß-III TUBULIN to highlight the cell bodies, axons and dendrites of the 
BRN3 positive and BRN3 negative cells in a population of retinal progenitor cells. ICC analysis 
revealed 2 populations of retinal progenitor cells, one proportion of the cells that were double 
positive for BRN3 and ß-III TUBULIN indicative of RGC neurons and another proportion that 
was negative for BRN3 but positive for ß-III TUBULIN indicative of non-RGC retinal neurons 
(Figure 28: A, B). The DAPI dye was used for identification of nuclei. Using the quantification 
tools on the Leica 5500 upright epifluorescence microscope, the areas occupied by the cell bodies 
were measured for 4 different sets of experiments and the values quantified using the unpaired 
student’s t-test (Figure 28). An average of at least 15 BRN3 positive and 20 BRN3 negative cells 
were measured for each experiment The comparatively analysis revealed a statistically significant 
(p < 0.005) difference between the two population where the RGCs had a mean cell body size of 
102.18 square microns (S.E. of 9.35) where was the non-RGC population had a very consistent 
mean cell size value of 67.17 square microns (S.E. of 0.88).  
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4.2.3.3 Comparison of RGCs and Photoreceptor Neurite Lengths 
To identify differences in neurite lengths between RGCs and other retinal cell types such as 
photoreceptors, this study established an important criterion for the classification of RGC by 
measuring the lengths of axons of the derived RGCs vs neurite lengths of photoreceptors 
differentiated from the same human iPS cell line. RGCs were triple-labeled for BRN3, MAP2, 
and axon-specific protein TAU (Figure 29: A). Photoreceptors were derived in culture after 70 
days of differentiation and their neurites were identified by the expression of the photoreceptor-
specific, calcium binding protein, RECOVERIN (Figure 29: B). The lengths were measured in 
microns and the data quantified using the unpaired student’s t-test, for 3 different sets of 
experiments (Figure 29). An average of 15 RGCs axons and 30 photoreceptor segments were 
measured for each experiment. The difference in lengths were highly significant (p < 0.001) with 
the RGC axons measuring at a mean length of 95.31 microns (S.E. of 6.28) and the photoreceptor 
neurite lengths at 29.18 microns (S.E. of 3.67).  
 
4.2.4 RT-PCR and qPCR Analysis of RGCs  
The expression of RGC-related genes was further determined by PCR analysis and quantification. 
Transcription factors associated with in vivo RGC development including the basic helix-loop-
helix ATOH7 (MATH5) is known to be highly specific for the early derivation of RGCs and 
known to regulate critical downstream targets of RGC differentiation, including BRN3B [18, 20]. 
THY1.2 is a cell surface glycoprotein that is used to identify RGC populations in later retinal 
histogenesis [124]. These two genes are highly specific to RGCs in the retina. RT-PCR analysis 
of cDNA synthesized from RNA isolated after 40 days of differentiation of human iPS cells 
revealed increased levels of RGC transcripts, BRN3, ATOH7, THY1.2, and PAX6 (Figure 30). 
PAX6 identified a broad stage of retinal progenitors including a possible restriction to RGC cell 
fate as was confirmed in ICC analysis. Further, the expression levels of BRN3 and PAX6 were 
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quantified over a time course from day 0 to day 40 of differentiation to identify the gradual 
increase in RGC specification from human iPS cells (Figure 30).  
 
4.2.5 Differentiation of Astrocytes from Human iPS Cells 
Using our line of human iPS cells, this study next looked to derive a second important cell type 
associated in the ONH changes during glaucoma, retinal astrocytes. The differentiation of 
astrocytes from iPS cells was monitored over prolonged periods of time in culture and novel 
methods were established to enrich for the glial cell types. The first evidence of astrocytes in 
culture was observed after 60 days of differentiation. Non-retinal neurospheres at day 18 were 
separated manually and cultured separately in suspension with doses of RDM and 20ng/mL of 
EFG/FGF/Heparin (EFH) every alternate day until day 60 when they were subsequently plated 
down onto laminin-coated polyornithine coverslips for analysis by immunostaining. A subset of 
cells dramatically expressed the cytoskeletal intermediate filament protein, glial fibrillary acidic 
protein (GFAP) highly present in astrocytes confirming the appropriate differentiation to an 
astrocytic fate. After 60 days of differentiation, a significantly high number of cells were 
observed expressing GFAP and higher magnification analysis revealed the characteristic stellate 
type morphology of astrocytes with outward extending processes (Figure 31). In efforts to further 
characterize the differentiation and retinal specification of astrocytes, this study analyzed the 
development of astrocytes at later time points of differentiation. Brightfield microscopy revealed 
the progressive and stepwise increase in number and maturation of a subset of these astrocytes 
(Figure 32: A-C). Starting with a population of astrospheres around day 70, subsequent plating 
and growth of these spheres after 10 days revealed mixed populations of cells comprising of 
astrocytes and neuronal cells. In vitro passaging using accutase helped enrich for the mitotically 
active astrocytes within the mixed population of neuronal cells. After a couple of passages, there 
was a significant increase in the number of astrocyte-like cells compared to neurons. Cells with 
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anatomical features similar to both protoplasmic and fibrous astrocytes, with long, unbranched 
and short, branched processes were observed at later timepoints of differentiation. 
 
4.2.6 Anterior Specification of Astrocytes 
To determine the anterior nature of the astrocytes derived in culture, the study used 
immunostaining strategies to identify the presence of markers associated with anterior neural 
development and the absence of those associated with a more posterior nervous system 
phenotype. OTX2, a marker used to identify derivatives of the anterior neuroepithelium was used 
to characterize the anterior nature of the astrocytes. HOXB4, a transcription factor associated 
with posterior/ spinal cord development served as a measure for lack of posterior nervous system 
origin of the glial cells being derived in the study. The presence of astrocytes was confirmed by 
the translational expression of GFAP (Figure 33: A). ICC analysis revealed that after 125 days of 
differentiation, a high subset of astrocytes expressed the OTX2 protein but were almost 
completely negative for HOXB4, indicating the anterior nature of the astrocytes derived in culture 
(Figure 33: B,C). The importance of anterior specification of the astrocytes stems from the 
important concept that all retinal astrocytes are derived in early forebrain regions of the 
developing neural tube and eventually migrate through the optic nerve to take their position as 
astroglia in the retina. A complete lack of HOXB4 is indicative of such a pattern of derivation 
from the human iPS cells.  
 
4.2.7 Increase in GFAP Expression at Later Time Points of Differentiation 
Next, the study established the qualitative increase in GFAP and OTX2 expression in astrocytes 
with a comparative analysis at different time points on course of differentiation. Astrocytes were 
analyzed after approximately 100 days of differentiation by ICC (Figure 34: A). Similar ICC 
analysis was done after 150 days of differentiation. By 120 days, the astrocyte cultures were 
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passaged up to 3 times using accutase providing an enriched population of astrocytes in culture. 
Cells until then were maintained in RDM and 20ng/uL of EGF/FGF/ Heparin (EFH). To measure 
GFAP expression at 150 days of differentiation, astrospheres were plated onto laminin coated 
polyornithine 4-well plates and cultured without the growth factors but in the presence of 
FBS during the last month to provide further nutrient enrichment for better survival and 
maturation of this cell type. Indeed, ICC analysis revealed enhanced expression of GFAP over the 
time course of differentiation from 100 days to 150 days and more OTX2 positive cells compared 
to Day 125 (Figure 34: B,C). However, the qualitative increase in GFAP seemed to be attributed 
to the eventual loss of the mitotically active nature and further experiments were devised to study 
astrocyte doubling time and senescence as an important feature of further characterization of this 
in vitro derived cell type.  
 
4.2.8 Measurement of Astrocyte Proliferation/ Doubling Rate 
To measure proliferation statistics of astrocytes, a strategy was devised to maintain and passage 
astrocyte cultures at consistent time intervals for a predetermined period of time. To achieve this 
end, experiments were conducted simultaneously with both the human iPS cell lines in use for the 
experiments in this entire study, Usher iPS and TIPS-5 lines. Proliferating cultures of plated 
astrocytes were passaged every week for a total period of 4 weeks from day 100 to day 130 of 
differentiation. The passaging of astrocytes was accomplished with accutase as explained and 
cells were grown in RDM and 20ng/mL EFH. Beginning at each passage and for each subsequent 
passage, a total of 100,000 cells each were plated onto 2 wells of a 6-well plate and expanded in 
EFH for 1 week. At the end of each week, viable cell counts were taken from both wells with the 
aid of trypan blue solution and the average of the 2 numbers were determined to be the acceptable 
cell count for that passage. Similarly, counts were taken for rest of the time points for both cell 
lines and proliferation/ day and doubling times calculated (Figure 35). For the TIPS-5 iPS cell 
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line, there was a progressive decrease of proliferation and increase in doubling time of astrocytes 
measured. IJHE9OJ;FHEB?<;H7J?ED:;9H;7I;:<HEC7JF7II7=;JE		7D:
<EH J>;D;NJF7II7=;IEK8B?D= J?C;?D9H;7I;:<HEC:7OI<EHF7II7=; JE	
2.13, and 3.17 days for the next 3 passages respectively. For the Usher syndrome iPS cell line, a 
similar trend was observed however, the proliferation was not as pronounced as the TIPS-5 iPS 
cell line. Proliferation rates decH;7I;:<HEC7JF7II7=; JE		7D:
for the next 3 passages respectively. Similarly, the increase in doubling time measured 5.96 days 
at passage 1 to 6.03, 6.86, and 6.93 for the next 3 passages respectively. The presence of 
neuronal-like or proliferating neural progenitor cells was nullified by the almost lack of 
expression of PAX6 in these cultures after 125 days of differentiation. 
 
4.3 Discussion and Future Studies 
New avenues of disease research are under investigation after the discovery of human iPS cells 
by Yamanaka and colleagues in 2007. These cells are essentially embryonic-like in terms of their 
potency and can be coaxed to differentiate to potentially any cell type in the human body. The 
importance of directed differentiation of somatic cell types from ES/ iPS cells is critical for cell 
replacement strategies in degenerative diseases. Once an efficient protocol to do so has been 
established, work needs to be done to characterize, enhance, and purify such cell populations to 
be tested in preclinical and eventually clinically models of diseases.  
 
This works cites efforts to establish methods to derive and characterize the affected cell types in 
the most prevalent retinal degenerative disease, glaucoma. Tackling differentiation of 2 somatic 
cell types associated with the disease individually, this study is successful in using techniques 
including ICC and PCR, to characterize the derived somatic cells types by the expression of 
developmentally associated transcription factors specific to each cell type. Further approaches 
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were undertaken to characterize the morphological differences between RGCs and other 
neuroretinal cell types derived in the process. This study provides methods to identify RGC 
neurons in culture and discusses novel ways and valuable data for the quantification of 
morphological properties of RGCs including its bigger cell bodies and longer axons which can be 
used as identifying properties compared to other retinal neurons including the photoreceptors and 
interneurons. The amount of RGCs identified by the translational co-expression of BRN3 and 
#-&.?I7FHEC?I?D=DKC8;H7D:=?L;I787I?I JE8;KI;:<EH<KHJ>;H;D>7D9?D=J>;
yield of RGCs by intrinsic or extrinsic manipulation of the cell system. Further RGCs 
characterization is established by RT-PCR and qPCR experiments identifying RGC specific 
genes ATOH7 and THY1.2 and documenting the stepwise increase in BRN3 expression starting 
from a pluripotent iPS cell source through the neural and retina progenitor stages to the eventual 
derivation of RGCs. Experiments with similar goals have been attempted but require better 
optimization for definitive and replicable results. The study overall provides a robust way to 
generate RGCs in culture from human iPS cells. Human iPS cells were also shown to be 
successful in deriving astrocyte like cells identified by their physical and molecular 
characteristics. This work also demonstrates the ability to maintain and expand human iPS cells 
derived astrocytes in vitro and provides further characterization by measuring the doubling rates 
of these cell types. A timeline for the specification of the non-retinal neurospheres in suspension 
to growth as astrocytes as adherent cultures is shown in this study. In vitro passaging of 
astrocytes with accutase reveals an enrichment of astrocytes and decrease in progenitor and post-
mitotic neuronal cells. The anterior origin of these astrocytes is anticipated by determining the 
anterior nature of these cells as characterized by the expression of OTX2 and lack of the posterior 
markers, HOXB4. This work also provides evidence for the qualitative increase in GFAP 
expression within astrocyte populations as an indication of more survival and maturation at later 
time points up to 150 days of differentiation.  
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Overall, this work has shown methods to efficiently derive and characterize RGCs and astrocytes 
although much work still needs to be done. In future studies, the yield of RGCs could be 
increased by exogenous addition of growth factors known to be associated with RGCs 
specification or use overexpression of RGCs specific genes to improve its production. 
Electrophysiological studies of iPS-RGCs would be an elegant way to establish their functional 
properties. Prolonged differentiation of iPS cultures could be planned to further study the onset of 
more RGC related proteins and track changes in proteins used in this study. Astrocytes would 
need more molecular characterization with markers like S100ß, PAX2, and VIMENTIN. 
Identification of retina specific astrocytes as found dispersed in the nerve fiber layer and the optic 
nerve regions would be the next steps in further understanding this glial cell type. A major future 
application of this study is to use information from this work and apply the same to iPS cells 
derived from cells of glaucoma patients. One would then be able to successfully compare a 
diseased phenotype with a control to better understand the complications in vitro. Another area to 
explore will be to initiate a co-culture system of RGCs and retinal astrocytes where the dynamics 
of interactions between the 2 somatic cell types could provide significant insights as to how these 
cell types are affected and behave in glaucoma.  
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CHAPTER 5 – DISCUSSION 
 
The last decade has seen a capacious amount of increase in works related to stem cells and their 
application in different human organ systems. Different aspects of human biology have been 
under continuous study using the incredible potential of stem cells. The two breakthrough 
landmarks in the field spaced 9 years apart, human ES cells in 1998 and human iPS cells in 2007, 
have dramatically changed the landscape of studying human biology and finding cures for 
currently untreatable cell degenerative diseases. The discovery of iPS cells, more so, has been 
welcomed in the scientific community, as it does away with any ethical dilemmas of working 
with human embryos and at the same time bearing resemblances in function and appearance to 
the currently clinically acceptable human ES cells. The use of iPS cells in disease research is 
based on the goals of finding genetic and environmental cues of disease ontogeny and 
development, generating clinical grade cells that are transplantation competent, and identifying 
novel mechanisms and drugs that could intervene or completely halt disease progression.  
The research presented in this work, overall, demonstrates the promising ability of human iPS 
cells to be used as a model system for the study of retinal development and degenerative diseases. 
In this study, human iPS cells were successfully used to establish a developmentally analogous 
time line for the derivation of retinal cells, in addition to the differentiation of mature retinal 
neurons that are specifically affected in complex types of blinding diseases. From the first known 
studies identifying primate ES cell-derived RPE cells in 2002 [125],  the generation of retinal 
cells from  human pluripotent stem cell sources including ES cells and iPS cells, today, has been 
achieved by several labs with different efficiencies [30, 126-129]. This study provides in an 
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achievable time frame identification of the onset of specific retinal cell types and shows novel 
ways and strategies to characterize them.  
 
Using human iPS cells to study neurodegenerative diseases is a very popular research domain but 
is still restricted to the laboratory culture dish. The methods of generation of iPS cells make it less 
conducive to use in a human patient setting, although new virus/ integration free methods to 
derive iPS cells have been successfully reported [96, 99, 130]. Using human iPS cells to model 
retinal degenerative disease has only been a very recent endeavor, with the first reports for RP 
being published only in 2011 [49]. There have been proof-of-principle studies demonstrating the 
use of patient specific iPS cells to model diseases including gyrate atrophy and Best disease [107, 
109] and many more efforts are required to unravel the complexities associated with the highly 
prevalent retinal diseases like RP, AMD, and glaucoma. The use of iPS cells in culture can be 
used to either study disease progression and phenotype if using patient specific cells or be used to 
provide a novel source for functioning somatic cell types affected in the disease if working with 
wild type cell lines that can be transplanted into patients to reverse or slow down the progression 
of the disease. In this study, the above two concepts are simultaneously applied to someday 
develop tools to study blinding disorders including, Usher syndrome and glaucoma. 
 
The first half this work demonstrates the potency of the iPS cell line derived from skin fibroblasts 
of a patient with type III Usher syndrome, to differentiate in accordance to previously established 
studies, towards an anterior neuroepithelium and progressing through all major stages of retinal 
development. The differentiation of the Usher iPS cell line was assessed though the initial eye 
field specification, optic-vesicle definitive retinal progenitor stage, and finally to the final 
derivation of mature retinal cell types [107]. The patient specific cell line was characterized from 
its pluripotent stage termed as day 0 until 70 days of differentiation, during which the different 
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developmental checkpoints were analyzed by utilizing the expression of stage specific 
transcription factors and proteins. As described in chapter 3, establishing the pluripotency of the 
cell line is the most critical point, when working with stem cells. The completely undifferentiated 
state of the Usher syndrome iPS cell line was shown by its specific brightfield morphologies and 
molecular expression profiles. The anterior region of the developing neural tube gives rise to the 
future areas of brain and eyes which was shown by the expression of anterior neural and eye field 
specific-factors including, PAX6, OTX2, SIX6, RAX, LHX2. The separation of neurospheres in 
suspension for retinal differentiation was based on a method described previously [107]. The iPS-
retinal progenitor cells were characterized as neurons and subsequently cultured for greater 
lengths of time for generation or retinal cell types. After 40 days, the first signs of the outer 
pigmented layer of the retina, RPE, emerged. These were distinctly recognized by their 
cobblestone morphology and onset and gradual increase in brown-black pigmentation in 
brightfield. The expression of RPE related proteins including EZRIN and BESTROPHIN, 
identifying its apical-basal property respectively, and RPE65, CRALBP was shown in ICC and 
RT-PCR experiments further confirmed its specification. The generation of more neuroretinal cell 
types from a subset of retinal progenitor cells was shown, including RGCs and photoreceptors, 
after 70 days of differentiation. Using ICC analysis, a general trend was observed in the 
progression from an immature to a mature state of photoreceptors as identified by expression 
patterns of CRX and RECVOERIN. RGCs were also present as subsets in differentiated cells, 
identified definitely by the widely established RGCs marker, BRN3, a POU domain transcription 
factor. The BRN3 antibody used was capable of identifying all three forms of the protein 
including BRN3A, BRN3B, and BRN3C. Further specification was achieved by a subset of 
BRN3 positive cells expressing another transcription factor specific to RGCs and progenitors in 
the retina, ISLET1. In totality, the patient specific cell line was shown to be competent for 
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recapitulating retinal development in vitro and successful in deriving, in good amounts, 
photoreceptors as early as after 70 days of differentiation.  
 
The second half of this study concentrated on establishing a timeline for optimizing a protocol for 
the derivation of RGCs and astrocytes, affected cell types in glaucoma, from non-glaucoma 
patient iPS cells. Two iPS cell lines mentioned in the methods section were used interchangeably 
in this part of the work. The use of the Usher iPS cell line was justified because there is no known 
reason to believe it would affect the derivation of RGCs in culture. The results of this work 
further confirmed this theory. Based on the findings of a recent paper in the field that showed that 
RGCs can be detected at earlier timepoints, after 40 days of differentiation [122], this study 
confirmed the generation of RGCs from iPS cells at the same time point by identifying 
populations of cells expressing the RGC specific BRN3 and the neural cytoskeletal marker, ß-III 
TUBULIN. Tubulin positive neurites were observed to be specific and emanating from the 
BRN3/ DAPI double positive nuclei. Since BRN3 identifies a large subset of RGCs but not all of 
them [21, 131], the study further characterized the RGCs populations by immunostaining for 
restricted markers for RGCs in the retina, PAX6 and ISLET1. PAX6 is developmentally 
restricted to RGCs during later time points and is known to promote differentiation of retinal 
progenitor cells to non-photoreceptor neurons [132]. ICC revealed different populations of cells 
including a population that was only BRN3 positive, one that co-expressed BRN3 and ISLET1/ 
PAX6, another which was only positive for ISLET1 or PAX6, and the remaining cells that only 
stained for DAPI. Cell populations expressing BRN3 individually or in combination were 
definitive for RGCs specification, given its derivation through a retinal progenitor stage of cells. 
PAX6 is a broad neural progenitor marker and restriction to RGCs neurons is expected at later 
stages in in vitro culture. The expression of PAX6 together with BRN3 in the same cells, along 
with cells expressing these markers individually can be early signs of RGCs maturation and 
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PAX6 restriction. The study quantified the number of cells that doubly expressed BRN3 and 
ISLET1*2FFHEN?C7J;BOE<J>;JEJ7B9;BBI9E-expressed BRN3 and ISLET1. Total 
cells positive for only BRN3 or ISLET1 was around 18-E<7D:-E<
H;IF;9J?L;BO.>;I;DKC8;HI7H;=EE:?D:?97J?EDIJE:;H?L;87I?99ED9BKI?EDIEDM>;H;JE
start and what to expect when trying to increase or improve the yield in future studies. Similar 
studies looking at derivation of RGCs as cell replacement resources have been published with 
mouse ES cells reported to gen;H7J;7FFHEN?C7J;BO,( positive cells after 50 days of 
differentiation [133]. Another study with mouse iPS cellI=;D;H7J;:7HEKD:,( positive 
cells, after overexpression of the RGC specific MATH5 in addition to external factors including 
DKK1 and Noggin [134] -J?BB 7DEJ>;H IJK:O M7I EDBO 78B; JE =;D;H7J; 7FFHEN?C7J;BO  E<
RGC-like cells from mouse ES cells treated with FGF2 and SHH [135]. This study established a 
serum-free method to derive RGCs with better productive efficiencies without the addition of any 
exogenous factors and at an attainable time frame. Next, this work showed novel ways to 
characterize the RGCs derived from iPS cells. Morphological traits including bigger cell bodies 
and thicker and longer axons for conduction of the electrical impulse are features that distinguish 
RGCs from other cell types in the retina. The study used molecular approaches to firstly identify 
these dissimilarities and then quantify the differences. The differences in cell sizes were 
compared for BRN3/ ß-III TUBULIN double positive neurons with ß-III TUBULIN positive 
neurons that were BRN3 negative. All cell populations were derived from iPS-retinal progenitor 
cells. BRN3 positive nuclei of cells were surrounded by the ß-III TUBLIN staining identifying 
the cell body, dendrites, and axon. Cell body areas were demarcated using tools in the microscope 
and values of areas covered calculated. The differences in cell sizes between the two 
corresponding populations were clearly significant with a p value of 0.0047 and a mean cell body 
size of 102.18 square microns (S.E. of 9.35) for BRN3 positive neurons versus 61.17 square 
microns (S.E. of 0.88) for the BRN3 negative neurons. BRN3 negative neurons were consistently 
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measured to be of the same sizes. Using similar tools, RGC axons were identified by BRN3 
positive TAU positive cells. The lengths of these cells were measured in microns and compared 
to neurite lengths of photoreceptors derived from the same cell line. The differences in neurite 
lengths between these 2 neuroretinal cell types, 95.31 microns (S.E. of 6.28) for RGCs and 29.18 
microns (S.E. of 3.67) for photoreceptors demonstrates the ability of human iPS cells to generate 
RGCs with morphological traits similar to their in vivo counterparts (p = 0.0008). The second cell 
type in glaucoma that affects the ONH is the retinal astrocytes. In this study the derivation of 
astrocytes based on their brightfield morphologies and GFAP expression was achieved using the 
lines of iPS cells. A protocol to passage and purify these cell types was demonstrated using 
accutase that enriched for the non-post-mitotic astrocytes gradually from among a population of 
mixed astrocytes and neuronal cells. Astrocytes with different morphologies characteristics were 
observed at longer time points in culture, after approximately 110 days. Both protoplasmic: long 
cell bodies with unbranched processes, and fibrous type: short stellate shaped bodies with 
branched processes, type astrocytes were observed in brightfield. A gradual increase in GFAP 
and OTX2 expression was observed until 150 days of differentiation indicating more maturation 
and specification of astrocyte cells. The anterior nature of these astrocytes was established after a 
few passages with accutase by the positive expression of OTX2 after 125 days and lack of 
markers for posterior origins in the developing nervous system, HOXB4. The field of cells 
yielded a high number of OTX2 positive cells from the plated astrospheres, indicating the highly 
anterior nature of these cells. The non-post-mitotic nature of astrocytes was characterized by 
measuring the proliferation rate of astrocytes in a controlled protocol as described in chapter 4. 
The results revealed a gradual decrease in proliferation and increase in doubling time from day 
100 up to day 130. The doubling rate for astrocytes derived from TIPS-5 iPS cell line increased 
by a factor of approximately 1.29 days for the 4 passages. For the Usher iPS cell line, the 
doubling rate increased similarly by 1.05 days. The proliferation rates of cells was however quite 
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higher for the former cell line. This can indicate a property of cell line to cell line variation. The 
lack of progenitor cells in these cultures was confirmed by the very low levels of PAX6.  
 
Overall, this study provides novel insights into the use of human iPS cells in retinal disease 
research. It established a proof-of-principle study that affected cell types can be generated from 
patients suffering from Usher syndrome and such a system can be used to further study the 
neurogenetic abnormalities of this disease. Human iPS cells can also be used to generate RGCs 
and astrocytes with reasonable efficiency, both of which are cell types that degenerate in 
glaucoma. The study provided novel evidence of molecular and physical characterization of 
RGCs, and established the anterior nature of the astrocytes derived from iPS cells. The 
differentiation of RGCs and astrocytes from non-glaucoma patient derived iPS cells lays the 
groundwork for future disease modeling of this disorder by the direct applications of this study to 
glaucoma patient derived iPS cells and paves the way for future work in cell replacement and 
drug screening applications in glaucoma research. 
 
 
 
 
 
. 
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Table 1: List of Primary Antibodies Used for Immunocytochemistry Analysis 
 
 
 
 
 
 
 
  
  
Antibody Type Source Dilution 
Bestrophin Mouse monoclonal Chemicon 1:100 
ß-III Tubulin Rabbit polyclonal Covance 1:1000 
Brn3 Goat polyclonal Santa Cruz 1:200 
Chx10 Sheep polyclonal Exalpha Biologicals 1:200 
Crx Mouse monoclonal Abnova 1:100 
Ezrin Rabbit polyclonal Cell Signaling Technology 1:100 
GFAP Mouse monoclonal Chemicon 1:5000 
Hoxb4 Rat polyclonal MRC NIMR 1:50 
Islet1 Mouse monoclonal Columbia University 1:200 
Lhx2 Goat polyclonal Santa Cruz 1:1000 
MAP-2 Rabbit polyclonal Santa Cruz 1:200 
Nanog Goat polyclonal R&D Biosystems 1:20 
Oct4 Rabbit polyclonal Stemgent 1:100 
Otx2 Goat polyclonal R&D Biosystems 1:1000 
Pax6 Mouse polyclonal Stemgent 1:100 
Recoverin Rabbit polyclonal Chemicon 1:1000 
Six6 Rabbit polyclonal Sigma Life Science 1:200 
Sox1 Goat polyclonal R&D Biosystems 1:1000 
Sox2 Rabbit polyclonal R&D Biosystems 1:100 
SSEA-4 Mouse monoclonal Stemgent 1:100 
Tau Mouse monoclonal Santa Cruz 1:50 
Tra-1-60 Mouse monoclonal Stemgent 1:100 
Tra-1-81 Mouse monoclonal Stemgent 1:100 
ZO-1 Rabbit polyclonal Invitrogen 1:100 
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Table 2: List of Primers Used for RT-PCR Analysis 
Gene Forward (5’ – 3’) Reverse (5’ – 3’) Band Size (bp) 
α-fetoprotein AGA ACC TGT CAC  AAG CTG TG 
GAC AGC AAG CTG 
AGG ATG TC 676 
Atoh7 GAG CGC GCG TTG CAC 
GGG TCT CGT ACT 
TGG ACA GC 210 
Best1 GCA AGC AGG CGT  TTA GCA TGC C 
CTG GGA GAC GAT 
GTC CAC GGC T 92 
Brachyury ACC CAG TTC ATA  GCG GTG AC 
CAA TTG TCA TGG 
GAT TGC AG 392 
Brn3 GCA AGC AGG CGT  TTA GCA TGC C 
CTG GGA GAC GAT 
GTC CAC GGC T 344 
Chx10 ATT CAA CGA AGC  CCA CTA CCC AGA 
ATC CTT GGC TGA 
CTT GAG GAT GGA 229 
Cralbp  TTC AAG GGC TTT  ACC ATG CAG CAG 
AGT ACC ATG GCT 
GGT GGA TGA AGT 130 
Crx TAT TCT GTC AAC  GCC TTG GCC CTA 
TGC ATT TAG CCC 
TCC GGT TCT TGA 253 
Ezrin  ACC ACC ATG GAT  GCA GAG CTG GA 
ACA CTT CCC GGA 
GGC CGA TAG T 101 
Gapdh ACC ACA GTC CAT  GCC ATC AC 
TCC ACC ACC CTG 
TTG CTG TA 450 
Lhx2 CAA GAT CTC GGA  CCG CTA CT 
CCG TGG TCA GCA 
TCT TGT TA 284 
Mitf  TTC ACG AGC GTC  CTG TAT GCA GAT 
TTG CAA AGC AGG 
ATC CAT CAA GCC 106 
Nanog CAA AGG CAA  ACA ACC CAC TT 
TCT GCT GGA GGC 
TGA GGT AT 158 
Nr2e1 ATG GCA AAT TCT  GTG GCG CTG AAG 
GCG CTG ATT TCC 
CAA GTG CAT TCT 352 
Oct4 CGA GCA ATT TGC  CAA GCT CCT GAA 
TTC GGG CAC TGC 
AGG AAC AAA TTC 324 
Otx2 CAA CAG CAG AAT GGA GGT CA 
CTG GGT GGA AAG 
AGA GAA GCT G 
429, 190 
(qPCR) 
Pax6 CGG AGT GAA TCA  GCT CGG TG 
CCG CTT ATA CTG 
GGC TAT TTT GC 
301 (+5a), 259 
(-5a) 
Pedf  AGA TCT CAG CTG  CAA GAT TGC CCA 
ATG AAT GAA CTC 
GGA GGT GAG GCT 127 
Rax  GAA TCT CGA AAT  CTC AGC CC 
CTT CAC TAA TTT 
GCT CAG GAC 279 
RPE65 GCC CTC CTG CAC  AAG TTT GAC TTT 
AGT TGG TCT CTG 
TGC AAG CGT AGT 92 
Six3 CGA GCA GAA GAC GCA TTG CTT CAA 
CGG CCT TGG CTA 
TCA TAC ATC ACA 395 
Six6 ATT TGG GAC GGC  GAA CAG AAG ACA 
ATC CTG GAT GGG 
CAA CTC AGA TGT 384 
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Sox1 CAA TGC GGG GAG GAG AAG TC 
CTC TGG ACC AAA 
CTG TGG CG 464 
Sox2 CCC CCG GCG GCA  ATA GCA 
TCG GCG CCG GGG 
AGA TAC AT 448 
Thy 1.2 TAG TCG ACC AGA  GCC TTC GT 
GCC CTC ACA CTT 
GAC CAG TT 311 
ZO-1  AGA CCG TGC TGA  CTT CTG GAG ATT 
ACT TTG TTT GAA 
CAG GCT GAG CGG 101 
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Table 3: List of Primers Used for qRT-PCR Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Gene Forward (5’ – 3’) Reverse (5’ – 3’) Band Size (bp) 
ß-Actin GCG AGA AGA TGA CCC AGA TC 
CCA GTG GTA CGG 
CCA GAG G 103 
Brn3 AGC GCT CTC ACT  TAC CCT TAC ACA 
AAA TGG TGC ATC 
GGT CAT GCT TCC 94 
Pax6 AGT GAA TCA GCT CGG TGG TGT CTT 
TGC AGA ATT CGG 
GAA ATG TCG CAC 120 
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Figure 1: Development of the retina. (a) The formation of the eye is initiated in the 
regions of the neural plate. (b) The neural plate proceeds to fold upwards and inwards. (c) 
The optic grooves evaginate. (d) The two distinct optic vesicles now bulge further towards 
the surface ectoderm. (e) The optic vesicle coordinates with the head ectoderm to form the 
lens placode. (f) The optic vesicle now invaginates to form the optic cup and the 
specialized layers of retina and RPE. (g) The axons of RGCs are enclosed together at the 
close of the choroid fissure to form the optic nerve. (Adapted with permission from Nature 
Reviews Neuroscience, [5]) 
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Figure 2: Role of multiple transcription factors in the retina. The different types and 
combinations of transcription factors associated with the specification and differentiation 
of retinal cell types during development. (Adapted with permission from Brain Research, 
[15]) 
Figure 3: The Retina. The highly defined and layered structure of the retina comprises of 
5 sets of interconnected neurons and the outermost RPE. Light incident on the ventral part 
of the eye traverses through all layers to be processed by the photoreceptors first and then 
travel back towards to the RGCs and to the brain via the optic nerve. (Adapted with 
permission from Elsevier Books, [37]) 
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Figure 4: Different source of pluripotent stem cells. Sources of pluripotent stem cells 
during chronological stages of development. iPS cells are sources of pluripotent stem cells 
achieved by inducing mature somatic cells to an embryonic-like state via genetic 
reprogramming. (Adapted with permission from Cell, [71]) 
Figure 5: Disease Modeling 
Using Human iPS Cells. A 
schematic of how patient 
derived iPS cells can be used to 
model cellular degenerative 
diseases. Starting with somatic 
cells, e.g. skin, blood, of 
patients, these cells can be 
induced to become patient 
specific iPS cells that are 
isogenic in character. Disease 
specific iPS cells can then be 
directed to differentiate towards 
the affected cell type in vitro. 
Affected cell types derived can 
be analyzed for disease 
phenotype and progression, 
testing drug candidates, or 
transplantation after gene 
correction. (Adapted with 
permission from Nature Reviews 
Immunology, [53]) 
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Figure 6: Maintenance and passaging of human iPS cells. Passaging of human iPS 
cells starts by identifying, marking (A), and scraping out any spontaneously differentiated 
colonies. The colonies are made then incubated in dispase for 15-20 minutes to allow for 
loosening of colonies (B,C) and then mechanically dislodged, triturated, and replated in 
fresh mTeSRTM1 medium (D). 
Figure 7: Timeline for neural induction of human iPS cells. Human iPS cells were 
differentiated according to the timeline shown. iPS cells were differentiated as embryoid 
bodies and eased into NIM during the first 6 days. Embryoid bodies were then plated and 
grown as adherent clusters until day 16 in NIM. At day 16, the clusters were lifted and 
allowed to form spheres for the next 2 days in RDM. The spheres were differentiated for 
later time points in suspension. Starting day 30, high number of neural cells was observed 
in culture. 
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Figure 8: ICC Analysis of Pluripotency of Usher iPS Cells. Following 
numerous passages, Usher Syndrome iPS cells maintained the expression of 
all pluripotency-related characteristics examined by immunocytochemistry 
(A-F), including the transcription factors SOX2, OCT4, and NANOG (A, C, 
E).  Furthermore, these cells expressed pluripotency-related cell surface 
antigens such as TRA-1-60 (B), SSEA-4 (D), and TRA-1-81 (F). (Scale bars, 
15 µm in panels A-F). 
Figure 9: Brightfield stage of 
pluripotency. Colonies of Usher 
iPS cells exhibited typical 
pluripotent morphologies with 
tightly packed cells with a clearly 
defined and phase bright edges to 
each colony.   
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Figure 10: Transcript Analysis of 
Factors Associated with 
Pluripotency. RT-PCR analysis 
confirmed the expression of 
pluripotency-related genes, OCT4, 
NANOG, and SOX2, as well as the lack 
of expression of markers of 
differentiation, AFP (endoderm), 
BRAC (mesoderm), and PAX6 
(ectoderm). 
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Figure 11: ICC Analysis of Primitive Neural Induction of Usher iPS 
Cells. After 10 days of differentiation, immunocytochemistry results 
demonstrated near uniform expression of early neural developmental 
transcription factors including PAX6 (A), SOX1 (B), OTX2 (C), and LHX2 
(D). (Scale bars, 15 µm in panels A-D). 
Figure 12: Brightfield stage of 
neural induction. At day 10, 
neural progenitor cells were 
characterized as outwardly 
proliferating cells from plated 
embryoid bodies. 
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Figure 13: Transcript Analysis of 
Primitive Neural Induction of Usher 
iPS Cells. RT-PCR analysis confirmed 
the expression of numerous early 
neurodevelopmental transcription 
factors, PAX6, SOX1, OTX2, LHX2, 
including the expression of factors for 
eye field specification including, RAX, 
SIX3, SIX6, and TLL. 
Figure 14: Identification of retinal and non-retinal neurospheres. At day 18, two 
distinct populations of spheres were identified. One population of spheres expressed a 
uniform phase bright ring around its periphery and had an optic vesicle-like appearance 
(A) whereas the other population had a uniformly darker appearance with internalized 
rosettes (B). 
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Figure 15: ICC Analysis of Retinal Progenitor Cells Derived from Usher 
iPS Cells. (A-D) Following 20 days of differentiation, a subset of cells 
exhibited numerous characteristics of retinal progenitor cells, including the 
expression of key transcription factors including LHX2, PAX6, SIX6, and 
CHX10. (Scale bars, 15 µm in panels A-D). 
Figure 16: Transcript 
Analysis of Retinal 
Progenitor Cells Derived 
from Usher iPS Cells. 
Gene expression analysis 
further confirmed the 
expression of key 
transcription factors 
associated with retinal 
progenitor cells including, 
RAX, CHX10, PAX6, 
LHX2, and OTX2. 
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Figure 17: ICC Analysis of Neuronal Specification from Usher iPS Cells. 
(A, B) After 30 days of differentiation, cells exhibited numerous 
characteristics of neurons, including the expression of transcription factors 
PAX6 and OTX2, as well as the cytoskeletal proteins ß-III TUBULIN and 
MAP2. (Scale bars, 15 µm in panels A and B). 
Figure 18: Brightfield example 
of in vitro derived neuronal cells. 
Under brightfield microscopy, 
numerous neuronal morphologies 
were observed including well 
defined and emanating axonal like 
processes from in vitro derived 
neuronal cell bodies. 
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Figure 19: Identification of RPE Differentiation by increase in pigmentation. The 
successful generation of RPE cells from Usher iPS cells was identified after 40-50 
days of differentiation. RPE exhibited typical cobblestone morphologies with 
characteristic pigmentation that increased in intensity with increasing timepoints in 
culture (A, B). 
Figure 20: ICC analysis of RPE Differentiation from Usher iPS Cells. After 60 
days, RPE was characterized by immunocytochemistry. RPE cells co-expressed the 
tight junction protein ZO-1 and OTX2 (A-C), and stained positive for other RPE 
specific proteins including the apical-basal proteins, EZRIN and BEST1 respectively 
(D-F). 
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Figure 21: Transcript analysis of RPE Differentiation from Usher iPS 
Cells. Gene expression profiling of iPS derived RPE cells further confirmed 
the expression of RPE specific factors including MITF, RPE65, PEDF, and 
CRALBP. 
Figure 22: Transcript Analysis 
of Retinal Progenitor Cells at 
Day 70. Gene expression results 
after 70 days of differentiation 
revealed the expression of 
markers associated with retinal 
progenitor cells including the 
broad marker CHX10, and CRX, 
a transcription factor 
characteristic of photoreceptor 
precursors.  
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Figure 23: Differentiation of RGCs at day 70. The generation of RGCs from Usher 
iPS cells was analyzed by immunostaining after 70 days of differentiation. Subsets of 
retinal progenitor cells adopted characteristics of retinal ganglion cells, including the 
expression of the transcription factors BRN3 and ISLET1. (Scale bars, 15 µm). 
Figure 24: Differentiation of photoreceptors at day 70. ICC analysis of in vitro 
Usher iPS derived photoreceptors revealed expression of CRX and RECOVERIN, 
indicating a progressive increase from a more immature to a more mature 
photoreceptor cell type. (Scale bars, 15 µm). 
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Figure 25: Identification of RGC neurons at day 40.  RGCs were derived after 40 
days of differentiation and identified by the expression of the RGC specific 
transcription factor BRN3. The neural nature of RGCs were further characterized by 
co-expression of BRN3 with the neural cytoskeletal marker ß-III TUBULIN (A) and 
with the axon specific marker, TAU (B). (Scale bars 11 µm in panel A, 15 µm in panel 
B) 
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Figure 26: Further molecular characterization of RGCs. The differentiation of 
RGCs was further characterized by immunocytochemistry after 40 days of 
differentiation. (A) A subset of retinal progenitor cells co-expressed RGC specific 
factors BRN3 and ISLET1. (B) A population of cells was also double positive for 
BRN3 and PAX6, a neurodevelopmental marker known to be restricted to RGCs in 
the retina during later ontogenesis.  (Scale bars 6.25 µm in panel A, 3.40 µm in panel 
B) 
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Figure 27: Quantification of yield of RGCs. After 40 days of differentiation the 
amount of human iPS-derived RGCs was quantified by counting the number of cells 
FEI?J?L; <EH J>;,! IF;9?<?9C7HA;HI	 ,(7D: #-&.FFHEN?C7J;BO 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-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 E< J>; 9;BBIM;H; FEI?J?L; <EH J>; ;NFH;II?EDE< 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population of cells expressed both BRN3 and ISLET1. (Scale bar, 19 µm) 
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Figure 28: Quantification of cell 
sizes of RGCs. Cell body areas of cells 
expressing ß-III TUBULIN with (A) or 
without (B) BRN3 derived from the 
same set of retinal progenitor cells was 
analyzed. RGCs identified by the 
positive expression of BRN3 had a 
significantly greater mean cell soma 
area of 102.18 µm2 (S.E. of 9.35) 
compared to 67.17 µm2 (S.E. of 0.88) 
for that of other neuronal cell types 
derived in the process. (n=4, p<0.05). 
(Scale bars, 15 µm in panels A and B) 
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Figure 29: Quantification of RGCs 
and Photoreceptor neurite lengths. 
The difference in lengths between the 
human iPS-derived RGC axons and 
photoreceptor neurites was measured. 
RGC axons were identified by the co-
expression of BRN3 and TAU (A) 
whereas photoreceptors were identified 
by their mature expression of the 
RECOVERIN protein (B). 
Measurement revealed a statistically 
significant difference with a mean 
length of 95.31 µm (S.E. of 6.28) for 
RGCs compared to 29.18 µm (S.E. of 
3.67) for that of photoreceptors. 
(p<0.05). (Scale bars, 10 µm in panel 
A and 4.44 µm in panel B). 
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Figure 30: PCR analysis of RGCs specification. Gene expression analysis further 
confirmed the specification of RGCs from human iPS cells after 40 days of 
differentiation. RT-PCR revealed expression of RGC specific genes including BRN3, 
ATOH7, THY1.2 and PAX6. qPCR analysis further demonstrated the progressive increase 
in BRN3 expression pattern from day 0 to day 40 in 10 day intervals. A similar trend was 
observed with PAX6, expected to peak earlier due to early neural specification from 
human iPS cells. 
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Figure 31: Differentiation of astrocytes at day 60. First signs of astroglial cells 
were observed in culture after 60 days of differentiation. Astrocytes appeared in their 
characteristic stellate type morphology and expressed the astrocyte specific 
cytoskeleton protein GFAP. ICC also revealed characteristic elongated processes 
generally associated with glial cell types. (Scale bars, 15 µm) 
Figure 32: Brightfield timeline for in vitro astrocyte enrichment. In vitro culture 
and differentiation of the astrospheres (A) in suspension followed by passaging with 
accutase revealed a progressive increase in non-post-mitotic astrocyte numbers and 
specification (B-C) as identified under bright field microscopy over a period of 110 
days of differentiation.  
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Figure 33: Anterior specification of astrocytes. After 125 days of differentiation, a 
qualitative increase in the expression of GFAP was observed (A). The astrocytes also 
expressed OTX2, a marker for anterior neural development (B), and were negative for 
the expression of HOXB4, a marker associated with spinal cord/ventral neural 
development (C). (Scale bars, 15 µm in panels A and B, 6.90 µm in panel C). 
Figure 34: Long term differentiation of astrocytes. Prolonged differentiation of 
astrocytes in serum conditions revealed a higher amount of maturation of in vitro 
derived astrocytes identified by the qualitative increase in intensity and number and of 
cells expressing GFAP (A-B) and OTX2 (C) until 150 days of differentiation. (Scale 
bars, 15 µm in panels A-C). 
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Figure 35: Measurement of astrocyte proliferation/ doubling rate. Rates of astrocyte 
proliferation were analyzed for both iPS cell lines. A general trend of decreasing ability to 
divide was observed from day 100 to day 130 for both. However, the TIPS-5 iPS cell line 
was more proliferative indicative of less doubling time between passages (1.48 days for 
passage 1 to 1.72, 2.13, and 3.17 for the next 3 passages) compared to that of the Usher 
iPS cell line, (5.96 days at passage 1 to 6.03, 6.86, and 6.93 for the next 3 passages). 
